<SEC-DOCUMENT>0001213900-24-076949.txt : 20240909
<SEC-HEADER>0001213900-24-076949.hdr.sgml : 20240909
<ACCEPTANCE-DATETIME>20240909162915
ACCESSION NUMBER:		0001213900-24-076949
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240905
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240909
DATE AS OF CHANGE:		20240909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		241287579

	BUSINESS ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		3000 EL CAMINO REAL
		STREET 2:		BLDG 4, STE 200
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0213868-8k_180life.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ATNF="http://180lifesciences.com/20240905">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_ATNF_180lifesciences.com_20240905 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20240905_20240905 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000004" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20240905.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-09-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-05</xbrli:startDate>
        <xbrli:endDate>2024-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-052024-09-05_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-05</xbrli:startDate>
        <xbrli:endDate>2024-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-052024-09-05_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-05</xbrli:startDate>
        <xbrli:endDate>2024-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-size: 12pt"><b>FORM&#160;<span id="xdx_90C_edei--DocumentType_c20240905__20240905_z2RVmWj8RQol"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>PURSUANT TO SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>SECURITIES EXCHANGE
ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">Date of Report (Date of
earliest event reported):&#160;<span id="xdx_900_edei--DocumentPeriodEndDate_c20240905__20240905_zjYSQWTLK7Dj"><ix:nonNumeric contextRef="AsOf2024-09-05" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 5, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-size: 12pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20240905__20240905_z9PkiEHJK0T7"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000011" name="dei:EntityRegistrantName">180
LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20240905__20240905_zSFFbFbtsdN4"><ix:nonNumeric contextRef="AsOf2024-09-05" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20240905__20240905_zaVdb3DG6N6c"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000013" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20240905__20240905_zken3HMkU9B7"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000014" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction<br/>
of Incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20240905__20240905_zOaCRCtlR5Bd"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000015" name="dei:EntityAddressAddressLine1">3000 El Camino Real</ix:nonNumeric></span>,<span id="xdx_900_edei--EntityAddressAddressLine2_c20240905__20240905_zkTwnedlvnY9"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000016" name="dei:EntityAddressAddressLine2">&#160;Bldg. 4</ix:nonNumeric></span>,<span id="xdx_90D_edei--EntityAddressAddressLine3_c20240905__20240905_z0nIcdGK6eq1"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000017" name="dei:EntityAddressAddressLine3">&#160;Suite 200</ix:nonNumeric></span><br/>
<span id="xdx_90B_edei--EntityAddressCityOrTown_c20240905__20240905_ztDV0u7v2LNi"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000018" name="dei:EntityAddressCityOrTown">Palo Alto</ix:nonNumeric></span>,&#160;<span id="xdx_904_edei--EntityAddressStateOrProvince_c20240905__20240905_zmQS8XMTLZ2k"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000019" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20240905__20240905_zXVuLHjgfSii"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000020" name="dei:EntityAddressPostalZipCode">94306</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code:&#160;<b><span style="text-decoration: underline">(<span id="xdx_903_edei--CityAreaCode_c20240905__20240905_zkWJEsoMucgh"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000021" name="dei:CityAreaCode">650</ix:nonNumeric></span>)&#160;<span id="xdx_907_edei--LocalPhoneNumber_c20240905__20240905_zffTF92zMefj"><ix:nonNumeric contextRef="AsOf2024-09-05" id="Fact000022" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate&#160;box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see&#160;</i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.15pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--WrittenCommunications_c20240905__20240905_zVUXIosbK5Uj"><ix:nonNumeric contextRef="AsOf2024-09-05" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SolicitingMaterial_c20240905__20240905_zEhuWQO7lkbi"><ix:nonNumeric contextRef="AsOf2024-09-05" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20240905__20240905_znz4Y2IXNR06"><ix:nonNumeric contextRef="AsOf2024-09-05" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20240905__20240905_zmB332rICpA9"><ix:nonNumeric contextRef="AsOf2024-09-05" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e 4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Securities registered
pursuant to Section 12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20240905__20240905__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zfsL58FKnLv9"><ix:nonNumeric contextRef="From2024-09-052024-09-05_custom_CommonStockParValue0.0001PerShareMember" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20240905__20240905__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zZb7P143cEoc"><ix:nonNumeric contextRef="From2024-09-052024-09-05_custom_CommonStockParValue0.0001PerShareMember" id="Fact000028" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&#160;<span id="xdx_90E_edei--SecurityExchangeName_c20240905__20240905__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zY7J65FFctPj"><ix:nonNumeric contextRef="From2024-09-052024-09-05_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20240905__20240905__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zL5tP4nSFs5c"><ix:nonNumeric contextRef="From2024-09-052024-09-05_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000030" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20240905__20240905__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zzskbtWBZSmi"><ix:nonNumeric contextRef="From2024-09-052024-09-05_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000031" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&#160;<span id="xdx_908_edei--SecurityExchangeName_c20240905__20240905__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zt7lyYtQBci3"><ix:nonNumeric contextRef="From2024-09-052024-09-05_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>&#160;Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)&#160;or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Emerging growth company&#160;<span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20240905__20240905_zx69rKIUtjHb"><ix:nonNumeric contextRef="AsOf2024-09-05" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective on September 5,
2024, 180 Life Sciences Corp.&#8217;s (the &#8220;<span style="text-decoration: underline">Company&#8217;s</span>&#8221;) wholly-owned subsidiary, Cannbiorex Pharma Ltd., a U.K.
corporation (&#8220;<span style="text-decoration: underline">Cannbiorex</span>&#8221;) and the Company, entered into a Separation and Release Agreement with Sir Marc Feldmann,
the former Co-Executive Chairman of the Company, the former Chief Executive Officer of Cannbiorex, and the current director of Cannbiorex,
which was amended to clarify such agreement effective September 5, 2024 (as amended, the &#8220;<span style="text-decoration: underline">Separation Agreement</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Separation Agreement,
the Company agreed to issue Sir Feldmann 57,328 shares of common stock and options to purchase 20,000 shares of common stock with a term
of two years and an exercise price of $1.95 per share, the closing sales price of the Company&#8217;s common stock on September 5, 2024,
under the Company&#8217;s Second Amended and Restated Omnibus Incentive Plan to satisfy amounts owed to Sir Feldmann in consideration
for services previously rendered to Cannbiorex. Under the Separation Agreement, Sir Feldmann provided a customary general release to Cannbiorex
and the Company, the Company and Cannbiorex provided a release to Sir Feldmann, subject to certain exceptions, and Sir Feldmann also agreed
to certain confidentiality, non-disclosure, non-solicitation, non-disparagement, and cooperation covenants in favor of the Company and
Cannbiorex. The shares are expected to be issued on September 9, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also effective on September
5, 2024, the Company entered into an Indemnification Agreement with Sir Feldmann to provide for indemnification to Sir Feldmann under
Delaware law. Among other things, consistent with the Company&#8217;s Bylaws, the Indemnification Agreement generally requires that the
Company (i) indemnify Sir Feldmann from and against all expenses and liabilities with respect to proceedings to which Sir Feldmann may
be subject by reason of Sir Feldmann&#8217;s service to the Company and its subsidiaries to the fullest extent authorized or permitted
by Delaware law and (ii) advance all expenses incurred by Sir Feldmann in connection with the investigation, defense, settlement or appeal
of any proceeding, and in connection with any proceeding to enforce Sir Feldmann&#8217;s rights under the Indemnification Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summary of the
Separation Agreement and Indemnification Agreement is a summary only and is qualified in its entirety by reference to the Separation Agreement
(as amended) and Indemnification, copies of which are attached hereto as&#160;<span style="text-decoration: underline">Exhibits 10.1</span>&#160;and <span style="text-decoration: underline">10.2</span>, respectively
and are incorporated into this&#160;<span style="text-decoration: underline">Item 1.01</span>&#160;by reference in their entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">After
the issuance of the shares of common stock to Sir Feldmann discussed above, the Company has 1,026,930 shares of common stock issued and
outstanding</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Item 9.01 Financial Statements
and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; padding: 0pt; width: 9%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="padding: 0pt; text-align: justify; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding: 0pt; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><a href="ea021386801ex10-1_180life.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: none">Separation and Release Agreement dated September 5, 2024 and First Amendment to Separation and Release Agreement dated September 5, 2024, by and between Cannbiorex Pharma Ltd., 180 Life Sciences Corp. and Sir Marc Feldmann </span></span></a></td></tr>
  <tr style="background-color: White">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify; text-indent: 0pt"><a href="ea021386801ex10-2_180life.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: none">Indemnity Agreement dated September 3, 2024 and effective September 5, 2024, between 180 Life Sciences Corp. and Sir Marc Feldmann</span></span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL documents).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed herewith.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>
SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Date: September 9, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Blair Jordan</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blair Jordan</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kdFOwkAQRb+Af5g0PpKyrWK0b9ogMYI20KCvS5nKhnanmd0ifJJ/6XYLkQfdbLKZzJx772SDYBhM6UlVyPDxuJhBjnVTSYuwwBIZdYFuIn1+ScC9C/xUxrLU1pdnMCXHoGPGYXy9dg0/ulcGNwmI+5G4HcU3IO4SMYZsHgy6fkq6VBvUVskKpN5AxtSwQiv52Cvk8kCa6qO3WiEbRTqBKBR9+xtiEcXwSnv5RbwzMJulwWDozyCYMrWNm5ocLOqOhEmFtbMzPf17fZqiNZbq5F1yt5zJKWu52EqDy61kNG+lW7EmvbRU7OZYr5EdFIk4jsTDKc+ZBUvQnGgwHgcqoRcAr/CH84V+JnklqxZFKISIMmSf4R/XS9khNJJh37Fw1dPQuO/xIc6eP3cXlgw= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea021386801ex10-1_180life.htm
<DESCRIPTION>SEPARATION AND RELEASE AGREEMENT DATED SEPTEMBER 5, 2024 AND FIRST AMENDMENT TO SEPARATION AND RELEASE AGREEMENT DATED SEPTEMBER 5, 2024, BY AND BETWEEN CANNBIOREX PHARMA LTD., 180 LIFE SCIENCES CORP. AND SIR MARC FELDMAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SEPARATION AND RELEASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Separation and Release Agreement (this &ldquo;<B><U>Agreement and Release</U></B>&rdquo; or &ldquo;<B><U>Agreement</U></B>&rdquo;)&nbsp;dated
August 30, 2024, is made by and between Marc Feldmann, an individual (&ldquo;<B><U>Feldmann</U></B>&rdquo;)&nbsp;and Cannbiorex Pharma
Ltd., a U.K. corporation (&ldquo;<B><U>CBR</U></B>&rdquo;), a wholly-owned subsidiary of 180 Life Sciences Corp. (&ldquo;<B><U>180 LS</U></B>&rdquo;,
and 180 LS, together with CBR, the &ldquo;<B><U>Company</U></B>&rdquo;), and the Company&nbsp;(collectively referred to as the &ldquo;<B><U>Parties</U></B>&rdquo;
or individually referred to as a &ldquo;<B><U>Party</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Feldmann currently
serves as Chief Executive Officer of CBR;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
and Feldmann previously entered into an Employment Agreement, dated May 31, 2018, and effective November 6, 2020, a First Amendment to
Employment Agreement, dated April 27, 2022 (the &ldquo;<B><U>First Amendment</U></B>&rdquo;) and a Second Amendment to Employment Agreement
on January 1, 2024 (the &ldquo;<B><U>Second Amendment</U></B>&rdquo;) (collectively referred to herein as, the &ldquo;<B><U>Employment
Agreement</U></B>&rdquo;), pursuant to which Feldmann agreed to serve as an employee (Chief Executive Officer)&nbsp;of CBR;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Feldmann also
previously served as Co-Executive Chairman of 180 LS;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, after discussion
among the Parties, the Parties believe that it is in the best interest of Feldmann and CBR to terminate the Employment Agreement and mutually
terminate Feldmann&rsquo;s employment with CBR, but for Feldmann to remain as a Director of CBR;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Feldmann&rsquo;s
Employment Agreement and Feldmann&rsquo;s employment with CBR is hereby terminated effective July 31, 2024 (the &ldquo;<B><U>Separation&nbsp;Date</U></B>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Parties
wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Feldmann may have
against the Company and any of the Released Parties as defined below, including, but not limited to, any and all claims arising out of
or in any way related to Feldmann&rsquo;s employment with or separation from the Company, each pursuant to the terms and conditions of
this Agreement set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the mutual promises made herein and the Severance Payment (defined below), the receipt and sufficiency of which is acknowledge
and confirmed, Feldmann and the Company hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Severance Payment</U>.
Subject to Feldmann&rsquo;s compliance with the terms and conditions of this Agreement and Release, 180 LS agrees to (a)&nbsp;issue Feldmann
57,328 fully-vested shares of 180 LS&rsquo;s common stock; and (b)&nbsp;grant Feldmann options to purchase 20,000 shares of 180 LS&rsquo;s
common stock, which shall have a term of two years and an exercise price of $1.82 per share, (a), and (b), the &ldquo;<B><U>Severance
Payment</U></B>&rdquo;). The Severance Payment shall be paid within 15 days of the Separation Date (the &ldquo;<B><U>Payment Date</U></B>&rdquo;).
Feldmann agrees that the Severance Payment to be paid under this Agreement and Release is due solely from the Company and represents consideration
which would not otherwise be due to Feldmann. The options shall be subject in all cases to the equity compensation plan of the Company
under which they are granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Release of Further
Payments</U>. The consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is inclusive of any and all amounts, including but not
limited to attorneys&rsquo; fees, that may be claimed by Feldmann or on Feldmann&rsquo;s behalf against the Company. In furtherance of
the above, and without limiting any other term or condition of this Agreement and Release, Feldmann agrees to release any rights he may
have to, and to waive all rights of the Company to pay, other than as set forth in&nbsp;<U>Paragraph 1</U>, any severance fees set forth
in the Employment Agreement, any bonus, accrued compensation, reimbursement for unused vacation days, sick days or other benefits, in
connection with severance pay or otherwise, any stock or option compensation, and further acknowledges that he is not owed any funds from
the Company in connection with unreimbursed business expenses as of the date of this Agreement and Release and/or any other amounts due
under the Employment Agreement. Feldmann further agrees that he is owed by the Company, those amounts set forth in&nbsp;<U>Paragraph&nbsp;1</U>,
for any vacation time, sick time, paid time off or paid leave of absence, or in connection with any severance or deferred compensation
plan, if eligible, and that he has been given all time off or is being paid for all time off to which he was entitled under any policy
or law, including but not limited to leave under the Family and Medical Leave Act. Notwithstanding any other term or condition of this
Agreement and Release, Feldmann may elect to continue health insurance coverage, following the Separation Date, if eligible in accordance
with the provisions of COBRA regardless of whether the Company enters into this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>No Further Payments</U>.
Except as described in&nbsp;<U>Paragraph&nbsp;1</U>, Feldmann acknowledges and agrees that he is not entitled to any other compensation,
severance, benefits, stock compensation, options, severance pay, or other payments in connection with his engagement by, or employment
or positions with, the Company or the termination thereof, or pursuant to the Employment Agreement or the termination thereof or otherwise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Feldmann Acknowledgements</U>.
By entering into this Agreement and Release, Feldmann confirms and acknowledges the Separation Date and that Feldmann shall be deemed
to have voluntarily resigned from employment with CBR as of the Separation Date. Feldmann further acknowledges and confirms that Feldmann
has been paid or is being paid for any salary, wages, incentives, bonuses, commissions and any other type of compensation due to Feldmann,
for work performed through and including the Separation Date. Feldmann further acknowledges that, as of the date of Feldmann&rsquo;s signing
of this Agreement and Release, Feldmann has sustained no injury or illness related in any way to Feldmann&rsquo;s employment with the
Company for which a worker&rsquo;s compensation claim has not already been filed. Concurrently with Feldmann&rsquo;s entry into this Agreement,
Feldmann shall provide a written resignation, resigning as an officer of CBR. Feldmann represents that he does not have any pending lawsuits,
claims, or actions against the Company and has fully disclosed all lawsuits, claims, or actions to the Company prior to executing this
Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Feldmann&rsquo;s
General Release.</U>&nbsp;In return for the Company&rsquo;s agreement to provide Feldmann with the Severance Payment referred to in&nbsp;<U>Paragraph&nbsp;1</U>,
Feldmann agrees to the following, in addition to the other terms and conditions of this Agreement and Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a.&nbsp;<I><U>General
Release</U></I>. Feldmann, for Feldmann and Feldmann&rsquo;s heirs, beneficiaries, devisees, privies, executors, administrators, attorneys,
representatives, and agents, and Feldmann&rsquo;s and his assigns, successors and predecessors, hereby releases and forever discharges
the Company, and its subsidiaries and affiliates, and each of their officers, directors, employees, members, agents, attorneys, predecessors,
successors and assigns of each of the foregoing entities (collectively, the &ldquo;<B><U>Released Parties</U></B>&rdquo;), from any and
all actions, causes of action, suits, debts, claims, complaints, charges, contracts, controversies, agreements, promises, damages, counterclaims,
cross-claims, claims for costs and/or attorneys&rsquo; fees, judgments and demands whatsoever, in law or equity, known or unknown, Feldmann
ever had, now has, or may have against the Released Parties as of the date of Feldmann&rsquo;s signing of this Agreement and Release.
This release includes, but is not limited to, any claims for severance pay, restricted stock, restricted stock units, stock or option
compensation, any claims alleging breach of express or implied contract, wrongful discharge, constructive discharge, breach of an implied
covenant of good faith and fair dealing, negligent or intentional infliction of emotional distress, negligent supervision or retention,
violation of the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, Older Workers Benefit Protection Act
of 1990, the Workers Adjustment and Retraining Notification Act, the Rehabilitation Act of 1973, the Civil Rights Act of 1866, Title VII
of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans with Disabilities Act, Sections 1981 through 1988 of Title
42 of the United States Code, as amended, the Employee Retirement Income Security Act of 1974, the Immigration Reform and Control Act,
the Equal Pay Act of 1963, the Family and Medical Leave Act of 1993, the Fair Labor Standards Act of 1938, the Older Workers Benefit Protection
Act of 1990, the Occupational Safety and Health Act of 1970, the Worker Adjustment and Retraining Notification Act of 1989, the Genetic
Information Nondiscrimination Act of 2008, California Family Rights Act &ndash; Cal. Gov&rsquo;t Code &sect; 12945.2, California Fair
Employment and Housing Act &ndash; Cal. Gov&rsquo;t Code &sect; 12900 et seq., California Unruh Civil Rights Act &ndash; Cal. Civ. Code
&sect; 51 et seq., Statutory Provisions Regarding the Confidentiality of AIDS Information &ndash; Cal. Health &amp; Safety Code &sect;
120775 et seq., California Confidentiality of Medical Information Act &ndash; Cal. Civ. Code &sect; 56 et seq., California Parental Leave
Law &ndash; Cal. Lab. Code &sect; 230.7 et seq., California Military Personnel Bias Law &ndash; Cal. Mil. &amp; Vet. Code &sect; 394,
the California Occupational Safety and Health Act, as amended, and any applicable regulations thereunder, the California Consumer Credit
Reporting Agencies Act &ndash; Cal. Civ. Code &sect; 1785 et seq., California Investigative Consumer Reporting Agencies Act &ndash; Cal.
Civ. Code &sect; 1786 et seq., those provisions of the California Labor Code that lawfully may be released, the Sarbanes-Oxley Act of
2002, claims pursuant to any other federal, state or local law regarding discrimination, harassment or retaliation based on age, race,
sex, religion, national origin, marital status, disability, sexual orientation or any other unlawful basis or protected status or activity,
and claims for alleged violation of any other local, state or federal law, regulation, ordinance, public policy or common-law duty having
any bearing whatsoever upon the terms and conditions of, and/or the cessation of Feldmann&rsquo;s employment with and by the Company and/or
the termination of the Employment Agreement or relating to the Company or his employment with CBR or any services provided to 180 LS in
general, each to the extent allowed pursuant to applicable law. Along with such release, all benefits to Feldmann from the Company (i.e.,
health insurance coverage, 401(k)&nbsp;plans and life insurance (if any))&nbsp;will be terminated. The Released Parties can seek attorneys&rsquo;
fees, costs, or other damages arising from Feldmann for Feldmann&rsquo;s breach of the release. Feldmann agrees that, if any portion of
this release is found to be unenforceable, the remainder of the release will remain enforceable. This release does not include claims
that may not be released under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b.&nbsp;<I><U>Unknown
Claims</U></I>. Feldmann understands and agrees that the release set forth in Section 5.a above, extends to all claims of every nature,
known or unknown, suspected or unsuspected, past or present, and that any and all rights granted to Feldmann under Section 1542 of the
California Civil Code or any analogous federal law or regulation are hereby expressly waived. Said Section 1542 of the California Civil
Code reads as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>&ldquo;A general release does not extend
to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release
and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Feldmann hereby
specifically acknowledges and agrees that (i)&nbsp;Feldmann&rsquo;s waiver of known and unknown claims and of California Civil Code &sect;
1542 is knowing and voluntary; (ii)&nbsp;the Severance Payment is in addition to anything of value to which Feldmann already is entitled;
and (iii)&nbsp;but for this Agreement, Feldmann would not be entitled to the Severance Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c.&nbsp;<I><U>Specific
Release</U></I><U>.</U>&nbsp;Feldmann agrees not only to release and discharge the Released Parties from any and all claims against the
Released Parties that Feldmann could make on Feldmann&rsquo;s own behalf, but also those which may have been or may be made by any other
person or organization on Feldmann&rsquo;s behalf. Feldmann specifically waives any right to become, and promises not to become, a member
of any class in a case in which any claim or claims are asserted against any of the Released Parties based on any acts or omissions occurring
on or before the date of Feldmann&rsquo;s signing of this Agreement and Release. If Feldmann is asserted to be a member of a class in
a case against any of the Released Parties based on any acts or omissions occurring on or before the date of Feldmann&rsquo;s signing
of this Agreement and Release, Feldmann shall immediately withdraw with prejudice in writing from said class, if permitted by law to do
so. Feldmann agrees that Feldmann will not encourage or assist any person in filing or pursuing any proceeding, action, charge, complaint,
or claim against the Released Parties, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Nonwaivable Claims</U>.
This Agreement and Release is not intended to interfere with Feldmann&rsquo;s exercise of any protected, nonwaivable right, including
Feldmann&rsquo;s right to file a charge with the Equal Employment Opportunity Commission or other government agency. By entering into
this Agreement and Release, however, Feldmann acknowledges that the Severance Payment set forth herein is in addition to amounts the Company
owes Feldmann under the Employment Agreement, that the Company would not have agreed to pay such amounts to Feldmann if not for Feldmann
agreeing to the terms of this Agreement, such amount is in full satisfaction of any amounts to which Feldmann might be entitled and Feldmann
is forever discharging the Released Parties from any liability to Feldmann for any acts or omissions occurring on or before the date of
Feldmann&rsquo;s signing of this Agreement and Release. This Agreement and Release is also not intended to diminish any right of indemnity
that Feldmann may enjoy in respect of his actions or inactions during his tenure as an employee of CBR or as Executive Chairman of 180
LS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Claims Not Released</U>.
Feldmann is not waiving any rights hereunder that Feldmann may have to: (i)&nbsp;Feldmann&rsquo;s vested 180 LS equity grants or any other
vested accrued employee benefits under any of the Company&rsquo;s health, welfare, or retirement benefit plans as of the Separation Date
or unemployment claims (which the Company agrees not to contest); (ii)&nbsp;any rights or claims Feldmann may have for indemnification,
and/or contribution, advancement or payment of related expenses pursuant to any Indemnification Agreement entered into with the Company
(&ldquo;<B><U>Indemnification Agreement</U></B>&rdquo;), or any other written agreement with the Company, the Company&rsquo;s Bylaws or
other organizing documents, and/or under applicable law; (iii)&nbsp;benefits or rights to seek benefits under applicable workers&rsquo;
compensation (except as to claims under Labor Code sections 132a and 4553), unemployment insurance or indemnification statutes or pursue
claims which by law cannot be waived by signing this Agreement; (iv)&nbsp;enforce or challenge the validity of this Agreement; (v)&nbsp;coverage
under any directors and officers liability insurance, other insurance policies of the Company, COBRA or any similar state law; (vi)&nbsp;as
a shareholder of 180 LS, if applicable; and (vii)&nbsp;any claims arising after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>No Admission</U>.
Neither this Agreement and Release, nor anything contained herein, shall be construed as an admission by the Released Parties of any liability
or unlawful conduct whatsoever. The Parties hereto agree and understand that the consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is
in excess of that which the Company is obligated to provide to Feldmann, and that it is provided solely in consideration of Feldmann&rsquo;s
execution of this Agreement and Release. The Company and Feldmann agree that the consideration set forth in&nbsp;<U>Paragraph&nbsp;1</U>&nbsp;is
sufficient consideration for the release being given by Feldmann in&nbsp;<U>Paragraph&nbsp;5</U>, and for Feldmann&rsquo;s other promises
herein, including, but not limited to in&nbsp;<U>Paragraphs 9</U>&nbsp;and&nbsp;<U>10</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Confirmation of
No Company Property</U>. Feldmann&rsquo;s signature below constitutes Feldmann&rsquo;s agreement that he doesn&rsquo;t have any original
or copies of any files, notes, programs, correspondence (whether electronic or hard copy), intellectual property, documents, slides, computer
disks, printouts, reports, lists of the Company&rsquo;s clients or leads or referrals to prospective clients, nor does he have any other
media or property in his possession or control which contain or pertain to Confidential Information (as defined below)&nbsp;or any other
items provided to Feldmann by the Company, developed or obtained by Feldmann in connection with Feldmann&rsquo;s employment with CBR or
consulting service with 180 LS, or otherwise belonging to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Restrictive Covenants</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a.&nbsp;<U>Confidential
Information</U>. Feldmann understands and agrees that Feldmann may have learned or had access to, or assisted in the development of, highly
confidential and sensitive information and trade secrets about the Company, its operations and its clients, and that providing its clients
with appropriate assurances that their confidences will be protected is crucial to the Company&rsquo;s ability to obtain clients, maintain
good client relations, and conform to contractual obligations. &ldquo;<B><U>Confidential Information</U></B>&rdquo; means any non-public
information that relates to the actual or anticipated business or research and development of the Company, technical data, trade secrets
or know-how, and includes, but is not limited to: (i)&nbsp;financial and business information related to the Company, such as strategies
and plans for future business, new business, product or other development, potential acquisitions or divestitures, and new marketing ideas;
(ii)&nbsp;product and technical information related to the Company, such as product formulations, methods, intellectual property, patented
technology, patent pending technology, and technology which may be patented in the future, new and innovative product ideas, methods,
procedures, devices, equipment, machines, data processing programs, software, software codes, source codes, computer models, and research
and development projects; (iii)&nbsp;client and supplier information, such as the identity of the Company&rsquo;s clients and suppliers,
the names of representatives of the Company&rsquo;s clients and suppliers responsible for entering into contracts with the Company, the
amounts paid by such clients and suppliers to the Company, specific client needs and requirements, and leads and referrals to prospective
clients and suppliers; (iv)&nbsp;personnel information, such as the identity and number of the Company&rsquo;s other employees, their
salaries, bonuses, benefits, skills, qualifications, and abilities; (v)&nbsp;any and all information in whatever form relating to any
client or client of the Company, including but not limited to its business, employees, operations, systems, assets, liabilities, finances,
products, and marketing, selling, and operating practices; (vi)&nbsp;any information not included in (i)&nbsp;or (ii)&nbsp;above which
Feldmann knows or should know is subject to a restriction on disclosure or which Feldmann knows or should know is considered by the Company
or the Company&rsquo;s clients or suppliers or prospective clients or suppliers to be confidential, sensitive, proprietary, or a trade
secret or is not readily available to the public; (vii)&nbsp;intellectual property, including inventions and copyrightable works and (viii)&nbsp;any
information related to any governmental investigations. Confidential Information is not generally known or available to the general public,
but has been developed, compiled or acquired by the Company at its great effort and expense. Confidential Information can be in any form:
oral, written, or machine readable, including electronic files.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b.&nbsp;<U>Confidentiality
Requirements</U>. Feldmann acknowledges and agrees that the Company is engaged in a highly competitive business and that its competitive
position depends upon its ability to maintain the confidentiality of the Confidential Information, which was developed, compiled and acquired
by the Company at its great effort and expense. Feldmann further acknowledges and agrees that any disclosing, divulging, revealing or
using of any of the Confidential Information, other than as specifically authorized by the Company, will be highly detrimental to the
Company and will cause it to suffer serious loss of business and pecuniary damage. Accordingly, Feldmann agrees that Feldmann will not,
for any purpose whatsoever, directly or indirectly use, disseminate, or disclose to any person, organization, or entity Confidential Information,
except as expressly authorized by the highest executive officer of the Company or by order of a court of competent jurisdiction after
providing the Company with sufficient notice to contest such order (the &ldquo;<B><U>Confidentiality Requirements</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c.&nbsp;<U>Non-Use
of Confidential Information</U>. Feldmann agrees not to use, disclose to others, or permit anyone access to any of the Company&rsquo;s
trade secrets or confidential or proprietary information without the Company&rsquo;s express consent, and to return immediately to the
Company all of the Company&rsquo;s property, including all files related to the Company, upon termination of Feldmann&rsquo;s employment.
Feldmann shall not retain any copy or other reproduction whatsoever of any Company property after the termination of Feldmann&rsquo;s
employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d.&nbsp;<U>Mutual
Non-Disparagement</U>. The Company, Feldmann and Released Parties agree not to say, write or cause to be said, disseminated, published,
issued, communicated or written, any statement that may be considered defamatory, derogatory, or disparaging of each other&nbsp;<FONT STYLE="background-color: white">concerning
Feldmann, the Company or any Released Party, Feldmann&rsquo;s employment with the Company, acts occurring before the signing of this Agreement
and Release, before the Separation Date or relating to this Agreement and Release and the matters covered hereby, or any other matter
whatsoever, provided that nothing shall prohibit Feldmann from communicating any concerns about potential violations of law, rule or regulation
to the Securities and Exchange Commission, Occupational Safety and Health Administration or any other government authority or self-regulatory
agency (collectively, &ldquo;<B><U>Agencies</U></B>&rdquo;), or prohibit Feldmann from discussing any such matters with any Agency</FONT>&nbsp;(collectively,
the &ldquo;<B><U>Non-Disparagement Requirements</U></B>&rdquo;). Nothing in this agreement prevents Feldmann from discussing or disclosing
information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Feldmann has reason to
believe is unlawful. Nothing in this Agreement prevents or restricts Feldmann from disclosing factual information relating to claims of
harassment, discrimination, or retaliation under the Fair Employment and Housing Act (FEHA), the Equal Employment Opportunity Commission,
or a state or local commission on human rights, or any self-regulatory organization regarding possible violations of law, including claims
based on race, sexual orientation, religion, color, national origin, ancestry, disability, medical condition, and age. Further, nothing
in this Agreement or any other agreement by and between the Company and Feldmann shall prohibit or restrict Feldmann from (i)&nbsp;voluntarily
communicating with an attorney retained by Feldmann, (ii)&nbsp;initiating, testifying, assisting, complying with a subpoena from, or participating
in any manner with an investigation conducted by any Agencies, (iii)&nbsp;recovering a Securities and Exchange Commission whistleblower
award as provided under Section 21F of the Securities Exchange Act of 1934, (iv)&nbsp;disclosing any confidential information to a court
or other administrative or legislative body in response to a subpoena, provided that Feldmann first promptly notifies and provides the
Company with the opportunity to seek, and join in its efforts at the sole expense of the Company, to challenge the subpoena or obtain
a protective order limiting its disclosure, or other appropriate remedy, or (v)&nbsp;filing or disclosing any facts necessary to receive
unemployment insurance, Medicaid or other public benefits to which Feldmann is entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e.&nbsp;<FONT STYLE="background-color: white"><U>Non-Interference</U>.
For a period of one (1)&nbsp;year from the Separation Date (the &ldquo;<B><U>Non-Solicitation Period</U></B>&rdquo;),&nbsp;</FONT>Feldmann
agrees to n<FONT STYLE="background-color: white">ot interfere with the Company&rsquo;s and any of its affiliates&rsquo; business relationships
with their employees, consultants, representatives, customers, researchers or suppliers by directly and actively soliciting, recruiting
or encouraging same for employment with Feldmann or any future employer of Feldmann or to leave the service of the Company or its affiliate(s),
unless granted prior permission by the Company, in writing. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f.&nbsp;<U>Reasonableness</U>.
Feldmann acknowledges and agrees that the restrictions set forth in this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp;are critical and necessary
to protect the Company&rsquo;s legitimate business interests (including the protection of its Confidential Information); are reasonably
drawn to this end with respect to duration, scope, and otherwise; are not unduly burdensome; are not injurious to the public interest;
and are supported by adequate consideration. Feldmann also acknowledges and agrees that the Company would be irreparably damaged if Feldmann
were to breach the covenants set forth in this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp; <FONT STYLE="background-color: white">and in the event
that Feldmann breaches any of the provisions in&nbsp;<U>Paragraph&nbsp;10</U>, The Company will be entitled to injunctive relief, in addition
to any other damages to which it may be entitled as well as the costs and reasonable attorneys&rsquo; fees it incurs in enforcing its
rights under this section. Feldmann further acknowledges that any breach or claimed breach of the provisions set forth in this Agreement
will not be a defense to enforcement of the restrictions set forth in this&nbsp;<U>Paragraph&nbsp;10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g.&nbsp;<FONT STYLE="background-color: white"><U>Invalid
or Unenforceable Provisions</U>. Each word, phrase, sentence, Paragraph&nbsp;or provision (each a &ldquo;<B><U>Provision</U></B>&rdquo;)&nbsp;of
this&nbsp;<U>Paragraph&nbsp;10</U>&nbsp;is severable. If any Provision of this&nbsp;<U>Paragraph&nbsp;10&nbsp;</U>is invalid or unenforceable,
such invalidity or unenforceability shall not affect the validity or enforceability of the remaining Provisions of this Agreement and
Release or this&nbsp;<U>Paragraph&nbsp;10</U>. If any Provision is deemed invalid or unenforceable for any reason, it is the Parties&rsquo;
intention that such covenants be equitably reformed, stricken or modified to the extent necessary to render them valid and enforceable
in all respects. In the event that the time period and/or geographic scope referenced above is deemed unreasonable, overbroad, or otherwise
invalid, it is the Parties&rsquo; intention that the enforcing court reduce or modify the time period and/or geographic scope to the extent
necessary to render such covenants reasonable, valid, and enforceable in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11. <U>Assistance
Following Termination</U>. Feldmann agrees that, following the Separation Date, he will cooperate fully with the Company upon
request in all matters relating to the completion of his pending work on behalf of the Company and in connection with the orderly
transition of such work to such other employees as the Company may designate. The Company will reimburse Feldmann for any reasonable
out-of-pocket expenses incurred pursuant to his duties under this&nbsp;<U>Paragraph&nbsp;11</U>, after the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Cooperation in
Investigations and Litigation</U>. In connection with the Company&rsquo;s pending legal matters and in the event the Company becomes involved
in any future investigations or legal proceedings of any nature, related directly or indirectly to events which occurred during Feldmann&rsquo;s
employment and about which Feldmann has personal knowledge, Feldmann agrees that Feldmann will, at any future time, be available upon
reasonable notice from the Company, with or without subpoena, to answer discovery requests, give depositions, or testify, with respect
to matters of which Feldmann has or may have knowledge as a result of or in connection with Feldmann&rsquo;s employment relationship with
the Company. In performing Feldmann&rsquo;s obligations under this paragraph to testify or otherwise provide information, Feldmann agrees
that Feldmann will truthfully, forthrightly, and completely provide the information requested. Feldmann further agrees that Feldmann will
not be compensated in any way by the Company for Feldmann&rsquo;s cooperation with the Company in connection with any litigation or other
activity covered by this paragraph, except that Feldmann shall be reimbursed as permitted by law for any reasonable expenses that Feldmann
incurs in providing testimony or other assistance to the Company under this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>Requests for References</U>.
The Company will confirm Feldmann&rsquo;s job title, dates of employment and, with written authorization from Feldmann, Feldmann&rsquo;s
salary in connection with any requests for references for Feldmann&rsquo;s potential future employers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Costs and Fees
Incurred</U>. Each Party shall bear its own costs and attorneys&rsquo; fees, if any, incurred in connection with this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Modifications</U>.
This Agreement and Release contains the full agreement of the Parties and may not be modified, altered, changed or terminated except upon
the express prior written consent of Feldmann and the Company or their authorized agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Acknowledgements</U>.
Feldmann acknowledges and agrees that: (a)&nbsp;no promise or inducement for this Agreement and Release has been made except as set forth
in this Agreement and Release; (b)&nbsp;this Agreement and Release is executed by Feldmann of his own free will and volition, without
reliance upon any statement or representation by the Company except as set forth herein; (c)&nbsp;Feldmann is legally competent to execute
this Agreement and Release and to accept full responsibility therefor; (d)&nbsp;Feldmann has been given twenty-one (21)&nbsp;days within
which to consider this Agreement and Release; (e)&nbsp;Feldmann has used all or as much of that twenty-one (21)&nbsp;day period as Feldmann
deemed necessary to consider fully this Agreement and Release and, if Feldmann has not used the entire twenty-one (21)&nbsp;day period,
Feldmann waives that period not used; (f)&nbsp;Feldmann has read and fully understands the meaning of each provision of this Agreement
and Release; (g)&nbsp;the Company has advised Feldmann to consult with an attorney concerning this Agreement and Release and has provided
Feldmann notice and an opportunity to retain an attorney; (h)&nbsp;Feldmann knowingly, freely and voluntarily enters into this Agreement
and Release; and (i)&nbsp;no fact, evidence, event, or transaction currently unknown to Feldmann but which may hereafter become known
to Feldmann shall affect in any manner the final and unconditional nature of the release stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Effective Date</U>.
This Agreement and Release shall become effective and enforceable on the eighth (8<SUP>th</SUP>)&nbsp;day following execution hereof by
Feldmann unless Feldmann revokes it by so advising the Company in writing before the end of the seventh (7<SUP>th</SUP>)&nbsp;day after
its execution by Feldmann (the &ldquo;<B><U>Effective Date</U></B>&rdquo;). In the event this Agreement is revoked prior to the Effective
Date, Feldmann shall immediately repay/return the Severance Payment (if paid prior to such date), and shall forfeit such Severance Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Company Release</U>.
Effective on the Effective Date, and in consideration for the release provided by Feldmann herein and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Company, on behalf of itself and its successors, assigns and other legal
representatives (all such other persons being hereinafter referred to collectively as &ldquo;<B><U>Releasors</U></B>&rdquo; and individually
as a &ldquo;<B><U>Releasor</U></B>&rdquo;), hereby absolutely, unconditionally and irrevocably releases, remises and forever discharges
Feldmann, and his successors and assigns (Feldmann and all such other persons being hereinafter referred to collectively as &ldquo;<B><U>Releasees</U></B>&rdquo;
and individually as a &ldquo;<B><U>Releasee</U></B>&rdquo;), of and from all demands, actions, causes of action, suits, covenants, contracts,
controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims,
defenses, rights of set-off, demands and liabilities whatsoever (individually, a &ldquo;<B><U>Claim</U></B>&rdquo; and collectively, &ldquo;<B><U>Claims</U></B>&rdquo;)
of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Releasors may now or hereafter
own, hold, have or claim to have against Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing
whatsoever which arises at any time on or prior to the Effective Date, except for Claims which relate to Feldmann&rsquo;s obligations
under this Agreement, claims relating to fraud or bad faith, breaches of Feldmann&rsquo;s fiduciary duties to the Company, rights to clawback
incentive consideration under the Company&rsquo;s clawback policies or applicable law, and/or any other rights or Claims which the Company
cannot waive under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">19.&nbsp;<U>[Intentionally Removed].</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;<U>Governing Law</U>.
This Agreement and Release shall be governed by and construed in accordance with the laws of the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.&nbsp;<U>Notices</U>. Any
notice or communication required or permitted to be given hereunder shall be in writing and deemed duly served on and given (i)&nbsp;when
delivered personally; (ii)&nbsp;three (3)&nbsp;business days after having been sent by priority or certified mail, return receipt requested,
postage prepaid; (iii)&nbsp;upon delivery by fax with written facsimile confirmation and electronically by email with written delivery
receipt; or (iv)&nbsp;one (1)&nbsp;business day after deposit with a commercial overnight carrier, with written verification of receipt.
Such notices shall be in writing and delivered to the address set forth below or to such other notice address as the other Party has provided
by written notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 2.5in"><FONT STYLE="font-size: 10pt"><I>If to Former Employer:</I></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>If to Former Employee:</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cannbiorex Pharma Ltd</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o 180 Life Sciences Corp.</P></TD>
    <TD><FONT STYLE="font-size: 10pt">Marc Feldmann</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3000 El Camino Real, Bldg. 4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">_____________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Suite 200</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">_____________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Palo Alto, CA 94306</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: [_______________]</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Email: _____________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22.&nbsp;<U>Waiver</U>. The
waiver by a Party of a breach of any provision herein shall not operate or be construed as a waiver of any subsequent breach by the other
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.&nbsp;<U>Severability</U>.
The provisions of this Agreement and Release are severable. Should any provision herein be declared invalid by a court of competent jurisdiction,
the remainder of this Agreement and Release will continue in force, and the Parties agree to renegotiate the invalidated provision in
good faith to accomplish its objective to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">24.&nbsp;<U>No Benefit for
Others</U>. The Parties acknowledge that Feldmann&rsquo;s right to the Severance Pay described herein shall be determined exclusively
under the provisions stated herein, and this Agreement and Release is not intended to, and does not, create rights for the benefit of
any other employee or person except in connection with the rights of the Released Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">25.&nbsp;<U>No Wrongful Conduct</U>.
Feldmann represents, warrants and covenants to each of the Released Parties that at no time prior to or contemporaneous with its execution
of this Agreement and Release has he (i)&nbsp;knowingly engaged in any wrongful conduct against, on behalf of or as the representative
or agent of the Company; (ii)&nbsp;breached any provision of the Employment Agreement; or (iii)&nbsp;violated any state, federal, local
or other law, including any securities laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">26.&nbsp;<U>No Assignment
or Transfer</U>. Feldmann warrants and represents that Feldmann has not heretofore assigned or transferred to any person not a party to
this Agreement and Release any released matter or any part or portion thereof and he shall defend, indemnify and hold 180 LS and each
Released Party harmless from and against any claim (including the payment of attorneys&rsquo; fees and costs actually incurred whether
or not litigation is commenced)&nbsp;based on or in connection with or arising out of any such assignment or transfer made, purported
or claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.&nbsp;<U>Not Assignable</U>.
This Agreement and Release is personal to Feldmann and shall not, without the prior written consent of the Company, be assignable by Feldmann.
This Agreement and Release shall inure to the benefit of and be binding upon the Company and its respective successors and assigns and
any such successor or assignee shall be deemed substituted for the Company under the terms of this Agreement and Release for all purposes.
As used herein, &ldquo;<B><U>successor</U></B>&rdquo; and &ldquo;<B><U>assignee</U></B>&rdquo; shall include any person, firm, corporation
or other business entity which at any time, whether by purchase, merger, acquisition of assets, or otherwise, directly or indirectly acquires
the ownership of the Company, acquires all or substantially all of the Company&rsquo;s assets, or to which the Company assigns this Agreement
and Release by operation of law or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">28.&nbsp;<U>Forfeiture of
Severance Payment</U>. Feldmann agrees that he will forfeit (and be forced to return)&nbsp;the Severance Payment payable by the Company
pursuant to this Agreement and Release&nbsp;if Feldmann challenges the validity of this Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.&nbsp;<U>Counterparts</U>.
This Agreement and Release may be signed in counterparts, and each counterpart shall be considered an original agreement for all purposes.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">30.&nbsp;<U>Clawback</U>.
Feldmann agrees that, notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation paid to
Feldmann under the Employment Agreement or any other agreement or arrangement with the Company which is subject to recovery under any
law, government regulation, or stock exchange listing requirement is be subject to such deductions and clawback pursuant to applicable
law and the Company&rsquo;s Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation, as may be amended or modified
from time to time. With respect to any potential clawback or recovery effected or subject to a determination by the Board of Directors
(the &ldquo;<B><U>Board</U></B>&rdquo;), the Board will make its determination for clawback or recovery in good faith, upon advice of
counsel, and in accordance with any applicable law or regulation, and to the extent permitted by law, only after (i)&nbsp;providing Feldmann
prior written notice of the deliberation of such potential clawback or recovery and (ii)&nbsp;providing Feldmann (and his counsel)&nbsp;an
opportunity to present to the Board all relevant information related to such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">31.&nbsp;<U>Section 409A</U>.
It is intended that this Agreement comply with, or be exempt from, Internal Revenue Code Section 409A and the final regulations and official
guidance thereunder (&ldquo;<B><U>Section 409A</U></B>&rdquo;)&nbsp;and any ambiguities and ambiguous terms herein will be interpreted
to so comply and/or be exempt from Section 409A. Each payment and benefit to be paid or provided under this Agreement (including without
limitation any Severance Payment)&nbsp;is intended to constitute a series of separate payments for purposes of Section 1.409A-2(b)(2)&nbsp;of
the Treasury Regulations. Feldmann acknowledges that if any provision of this Agreement (or of any award of compensation or benefits)&nbsp;would
cause Feldmann to incur any additional tax or interest under Section 409A and accompanying Treasury regulations and other authoritative
guidance, such additional tax and interest shall solely be his responsibility. The Company and Feldmann will work together in good faith
to consider either (i)&nbsp;amendments to this Agreement; or (ii)&nbsp;revisions to this Agreement with respect to the payment of any
awards, which are necessary or appropriate to avoid imposition of any additional tax or income recognition prior to the actual payment
to Feldmann under Section 409A. In no event will the Released Parties have any obligation, liability or responsibility to reimburse, indemnify
or hold harmless Feldmann for any taxes imposed, or other costs incurred, as a result of Section 409A. The Separation Date is intended
to constitute Feldmann&rsquo;s &ldquo;separation from service&rdquo; within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Remainder of page left intentionally blank. Signature
page follows.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Parties have hereunto set their hands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Marc Feldmann</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>180 Life Sciences Corp.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-size: 10pt">&nbsp;<I>/s/ Marc Feldmann</I></FONT></TD>
    <TD STYLE="width: 17%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Blair Jordan</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt">Printed Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Blair Jordan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Interim CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">September 5, 2024</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">September 3, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Cannbiorex Pharma Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Ozan Pamir</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt">Printed Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Ozan Pamir</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">CFO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">September 3, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Separation and Release Agreement</P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>FIRST AMENDMENT TO
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>SEPARATION AND RELEASE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This First Amendment to Separation
and Release Agreement (this &ldquo;<B><U>Amendment</U></B>&rdquo;), dated September 5,&nbsp;2024 and effective September 3,&nbsp;2024
(the &ldquo;<B><U>Effective Date</U></B>&rdquo;), amends that certain Separation and Release Agreement dated September 3, 2024 (the &ldquo;<B><U>Separation
Agreement</U></B>&rdquo;), by and between Sir Marc Feldmann, an individual (&ldquo;<B><U>Feldmann</U></B>&rdquo;) and Cannbiorex Pharma
Ltd., a U.K. corporation (&ldquo;<B><U>CBR</U></B>&rdquo;), a wholly-owned subsidiary of 180 Life Sciences Corp. (&ldquo;<B><U>180 LS</U></B>&rdquo;,
and 180 LS, together with CBR, the &ldquo;<B><U>Company</U></B>&rdquo;), and the Company (collectively referred to as the &ldquo;<B><U>Parties</U></B>&rdquo;
or individually referred to as a &ldquo;<B><U>Party</U></B>&rdquo;). Certain capitalized terms used below but not otherwise defined shall
have the meanings given to such terms in the Separation Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>WHEREAS</B>,
the Parties desire to enter into this Amendment to amend the Separation Agreement on the terms and subject to the conditions set forth
below.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>NOW,
THEREFORE</B>, in consideration of the premises and the mutual covenants, agreements, and considerations herein contained, and other good
and valuable consideration, which consideration the Parties hereby acknowledge and confirm the receipt and sufficiency thereof, the Parties
hereto agree as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.&nbsp;<U>Amendment
to Separation Agreement</U></B>. Effective as of the Effective Date <U>Section&nbsp;1</U> of the Separation Agreement shall be amended
and restated to read in its entirety as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;1. <U>Severance
Payment</U>. Subject to Feldmann&rsquo;s compliance with the terms and conditions of this Agreement and Release, 180 LS agrees to (a)
issue Feldmann 57,328 fully-vested shares of 180 LS&rsquo;s common stock; and (b) grant Feldmann options to purchase 20,000 shares of
180 LS&rsquo;s common stock, which shall have a term of two years and an exercise price equal to the Exercise Price, (a), and (b), the
&ldquo;<B>Severance Payment</B>&rdquo;). The Severance Payment shall be paid within 15 days of the Separation Date (the &ldquo;<B>Payment
Date</B>&rdquo;). Feldmann agrees that the Severance Payment to be paid under this Agreement and Release is due solely from the Company
and represents consideration which would not otherwise be due to Feldmann. The options shall be subject in all cases to the equity compensation
plan of the Company under which they are granted. &ldquo;<B>Exercise Price</B>&rdquo; shall mean the closing sales price of 180 LS&rsquo;
common stock on the Nasdaq Capital Market on the date that this Agreement is fully binding on all Parties hereto.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.&nbsp;<U>Consideration</U></B>.
Each of the Parties agrees and confirms by signing below that they have received valid consideration in connection with this Amendment
and the transactions contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 3</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">First Amendment to Separation Agreement</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.&nbsp;<U>Mutual Representations,
Covenants and Warranties</U></B>. Each of the Parties, for themselves and for the benefit of each of the other Parties hereto, represents,
covenants and warranties that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Such
Party has all requisite power and authority, corporate or otherwise, to execute and deliver this Amendment and to consummate the
transactions contemplated hereby and thereby. This Amendment constitutes the legal, valid and binding obligation of such Party
enforceable against such Party in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally and general equitable
principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The
execution and delivery by such Party and the consummation of the transactions contemplated hereby do not and shall not, by the lapse
of time, the giving of notice or otherwise: (i) constitute a violation of any law; or (ii) constitute a breach of any provision
contained in, or a default under, any governmental approval, any writ, injunction, order, judgment or decree of any governmental
authority or any contract to which such Party is bound or affected; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Any
individual executing this Amendment on behalf of an entity has authority to act on behalf of such entity and has been duly and
properly authorized to sign this Amendment on behalf of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.&nbsp;<U>Further
Assurances</U></B>. The Parties agree that, from time to time, each of them will take such other action and to execute, acknowledge and
deliver such contracts, deeds, or other documents as may be reasonably requested and necessary or appropriate to carry out the purposes
and intent of this Amendment and the transactions contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal">5.&nbsp;<U>Effect
of Amendment</U><FONT STYLE="font-weight: normal">. Upon the effectiveness of this Amendment, each reference in the Separation Agreement
to &ldquo;</FONT><U>Separation Agreement</U><FONT STYLE="font-weight: normal">&rdquo;, &ldquo;</FONT><U>Agreement,</U><FONT STYLE="font-weight: normal">&rdquo;
&ldquo;</FONT><U>hereunder,</U><FONT STYLE="font-weight: normal">&rdquo; &ldquo;</FONT><U>hereof,</U><FONT STYLE="font-weight: normal">&rdquo;
&ldquo;</FONT><U>herein</U><FONT STYLE="font-weight: normal">&rdquo; or words of like import shall mean and be a reference to such Separation
Agreement, as applicable, as modified and amended hereby.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal">6.&nbsp;<U>Separation
Agreement to Continue in Full Force and Effect</U><FONT STYLE="font-weight: normal">. Except as specifically modified or amended herein,
the Separation Agreement and the terms and conditions thereof shall remain in full force and effect.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.&nbsp;<U>Entire
Agreement</U></B>. This Amendment sets forth all of the promises, agreements, conditions, understandings, warranties and representations
among the Parties with respect to the transactions contemplated hereby and thereby, and supersedes all prior agreements, arrangements
and understandings between the Parties, whether written, oral or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.&nbsp;<U>Construction</U></B>.
In this Amendment words importing the singular number include the plural and vice versa; words importing the masculine gender include
the feminine and neuter genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.&nbsp;<U>Governing
Law</U></B>. The provisions of <U>Section 20</U> of the Separation Agreement are incorporated by reference herein in their entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.&nbsp;<U>Counterparts
and Signatures</U></B>. This Amendment and any signed agreement or instrument entered into in connection with this Amendment, and any
amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument.
Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic
mail (any such delivery, an &ldquo;<B><U>Electronic Delivery</U></B>&rdquo;) shall be treated in all manner and respects as an original
executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered
in person. No Party shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument
was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such Party
forever waives any such defense, except to the extent such defense relates to lack of authenticity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page left intentionally blank. Signature
page follows.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 3</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">First Amendment to Separation Agreement</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Parties hereto have executed this Amendment as of the day and year first above written to be effective as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>Marc Feldmann</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2"><B>180 Life Sciences Corp.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding-bottom: 1.5pt">Signature:</TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid">&nbsp;<I>/s/ Marc Feldmann</I></TD>
    <TD STYLE="width: 17%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt">Signature:</TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid"><I>/s/ Blair Jordan</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">Printed Name:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;Blair Jordan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">Interim CEO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">September 5, 2024</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: justify">September 5, 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Date</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>Cannbiorex Pharma Ltd.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt">Signature:</TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid"><I>/s/ Ozan Pamir</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">Printed Name:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">Ozan Pamir</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">CFO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: justify">September 5, 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page 3  of 3</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">First Amendment to Separation Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea021386801ex10-2_180life.htm
<DESCRIPTION>INDEMNITY AGREEMENT DATED SEPTEMBER 3, 2024 AND EFFECTIVE SEPTEMBER 5, 2024, BETWEEN 180 LIFE SCIENCES CORP. AND SIR MARC FELDMAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INDEMNITY AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS INDEMNITY AGREEMENT&nbsp;</B>(this
&ldquo;<B><I>Agreement</I></B>&rdquo;) is made as of September 3, 2024, by and between 180 LIFE SCIENCES CORP., a Delaware corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), and Sir Marc Feldmann (&ldquo;<B><I>Indemnitee</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, highly competent
persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided
with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising
out of their service to and activities on behalf of such corporations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Board
of Directors of the Company (the &ldquo;<B><I>Board</I></B>&rdquo;) has determined that, in order to attract and retain qualified individuals,
the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company
and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice
among publicly traded corporations and other business enterprises, the Company believes that, given current market conditions and trends,
such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers
and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming
litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise
itself. The Second Amended and Restated Certificate of Incorporation, as amended (the &ldquo;<B><I>Charter</I></B>&rdquo;) and Bylaws
of the Company require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification
pursuant to applicable provisions of the Delaware General Corporation Law (&ldquo;<B><I>DGCL</I></B>&rdquo;). The Charter, Bylaws and
the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts
may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification,
hold harmless, exoneration, advancement and reimbursement rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the uncertainties
relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Board
has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company&rsquo;s
stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, it is reasonable,
prudent and necessary for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance expenses
on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company
free from undue concern that they will not be so protected against liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, this Agreement
is a supplement to and in furtherance of the Charter and Bylaws of the Company and any resolutions adopted pursuant thereto, and shall
not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Indemnitee
may not be willing to serve as an officer or director, advisor or in another capacity to the Company or one or more of its subsidiaries
without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to
serve and to take on additional service for or on behalf of the Company and/or one or more of its subsidiaries, on the condition that
he be so indemnified; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TERMS AND CONDITIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1. &nbsp;SERVICES
TO THE COMPANY</B>. Indemnitee will serve or continue to serve as an officer, director, advisor, key employee or in any other capacity
of the Company or one or more of its subsidiaries, as applicable, for so long as Indemnitee is duly elected, appointed or retained or
until Indemnitee tenders his resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2. DEFINITIONS</B>.
As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">2.1. References
to &ldquo;<B><I>agent</I></B>&rdquo; shall mean any person who is or was a director, officer or employee of the Company or a subsidiary
of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a
director, officer, employee, advisor, fiduciary or other official of another corporation, partnership, limited liability company, joint
venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">2.2. The
terms &ldquo;<B><I>Beneficial Owner</I></B>&rdquo; and &ldquo;<B><I>Beneficial Ownership</I></B>&rdquo; shall have the meanings set forth
in Rule&nbsp;13d-3 promulgated under the Exchange Act (as defined below) as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">2.3. A &ldquo;<B><I>Change
in Control</I></B>&rdquo; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the
following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.1. <U>Acquisition
of Stock by Third Party</U>. Any Person (as defined below) is or becomes the Beneficial Owner, directly or indirectly, of securities
of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&rsquo;s then outstanding
securities entitled to vote generally in the election of directors, unless (1)&nbsp;the change in the relative Beneficial Ownership
of the Company&rsquo;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of
securities entitled to vote generally in the election of directors, or (2)&nbsp;such acquisition was approved in advance by the
Continuing Directors (as defined below) and such acquisition would not constitute a Change in Control under part 2.3.3&nbsp;of this
definition;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.2. <U>Change
in Board of Directors</U>. Individuals who, as of the date hereof, constitute the Board, and any new director whose election by the
Board or nomination for election by the Company&rsquo;s stockholders was approved by a vote of at least two thirds of the directors
then still in office who were directors on the date hereof or whose election for nomination for election was previously so approved
(collectively, the &ldquo;<B><I>Continuing Directors</I></B>&rdquo;), cease for any reason to constitute at least a majority of the
members of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.3. <U>Corporate
Transactions</U>. The effective date of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or
similar business combination, involving the Company and one or more businesses (a &ldquo;<B><I>Business Combination</I></B>&rdquo;),
in each case, unless, following such Business Combination: (1)&nbsp;all or substantially all of the individuals and entities who
were the Beneficial Owners of securities entitled to vote generally in the election of directors immediately prior to such Business
Combination beneficially own, directly or indirectly, more than 51% of the combined voting power of the then outstanding securities
of the Company entitled to vote generally in the election of directors resulting from such Business Combination (including, without
limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company&rsquo;s
assets either directly or through one or more Subsidiaries) in substantially the same proportions as their ownership immediately
prior to such Business Combination, of the securities entitled to vote generally in the election of directors; (2)&nbsp;no Person
(excluding any corporation resulting from such Business Combination) is the Beneficial Owner, directly or indirectly, of 15% or more
of the combined voting power of the then outstanding securities entitled to vote generally in the election of directors of the
surviving corporation except to the extent that such ownership existed prior to the Business Combination; and (3)&nbsp;at least a
majority of the Board of Directors of the corporation resulting from such Business Combination were Continuing Directors at the time
of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.3.4. <U>Liquidation</U>.
The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement or series of agreements for
the sale or disposition by the Company of all or substantially all of the Company&rsquo;s assets, other than factoring the
Company&rsquo;s current receivables or escrows due (or, if such approval is not required, the decision by the Board to proceed with
such a liquidation, sale, or disposition in one transaction or a series of related transactions); or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">2.3.5. <U>Other
Events</U>. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of
Schedule&nbsp;14A of Regulation&nbsp;14A (or a response to any similar item on any similar schedule or form) promulgated under the
Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4. &ldquo;<B><I>Corporate
Status</I></B>&rdquo; describes the status of a person who is or was a director, officer, trustee, general partner, managing member, fiduciary,
employee or agent of the Company, any Subsidiary of the Company, or of any other Enterprise (as defined below) which such person is or
was serving at the request of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5. &ldquo;<B><I>Delaware
Court</I></B>&rdquo; shall mean the Court of Chancery of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6.&nbsp; &ldquo;<B><I>Disinterested
Director</I></B>&rdquo; shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect
of which indemnification is sought by Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7. &ldquo;<B><I>Enterprise</I></B>&rdquo;
shall mean the Company and any other corporation, constituent corporation (including any constituent of a constituent) absorbed in a consolidation
or merger to which the Company (or any of its wholly owned subsidiaries) is a party, limited liability company, partnership, joint venture,
trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer,
trustee, general partner, managing member, fiduciary, employee or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.8.
&ldquo;<B><I>Exchange Act</I></B>&rdquo; shall mean the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.9. &ldquo;<B><I>Expenses</I></B>&rdquo;
shall include all direct and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all attorneys&rsquo;
fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators
and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax transmission
charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting, defending, preparing
to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or otherwise participating in,
a Proceeding (as defined below), including reasonable compensation for time spent by the Indemnitee for which he or she is not otherwise
compensated by the Company or any third party. Expenses also shall include Expenses incurred in connection with any appeal resulting from
any Proceeding (as defined below), including without limitation the principal, premium, security for, and other costs relating to any
cost bond, supersedeas bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by
Indemnitee or the amount of judgments or fines against Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.10.
&ldquo;<B><I>Independent Counsel</I></B>&rdquo; shall mean a law firm or a member of a law firm with significant experience in
matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i)&nbsp;the
Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee
under this Agreement, or of other indemnitees under similar indemnification agreements); or (ii)&nbsp;any other party to the
Proceeding (as defined below) giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term
&ldquo;Independent Counsel&rdquo; shall not include any person who, under the applicable standards of professional conduct then
prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine
Indemnitee&rsquo;s rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.11. References
to &ldquo;<B><I>fines</I></B>&rdquo; shall include any excise tax assessed on Indemnitee with respect to any employee benefit plan; references
to &ldquo;serving at the request of the Company&rdquo; shall include any service as a director, officer, employee, agent or fiduciary
of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to
an employee benefit plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably
believed to be in the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to
have acted in a manner &ldquo;not opposed to the best interests of the Company&rdquo; as referred to in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.12. The term &ldquo;<B><I>Person</I></B>&rdquo;
shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided, however,
that &ldquo;Person&rdquo; shall exclude: (i) the Company; (ii)&nbsp;any Subsidiaries (as defined below) of the Company; (iii)&nbsp;any
employment benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of any corporation owned, directly or indirectly,
by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company; and (iv)&nbsp;any
trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a Subsidiary (as defined below) of the
Company or of a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their
ownership of stock of the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.13. The term
&ldquo;<B><I>Proceeding</I></B>&rdquo; shall include any threatened, pending or completed action, suit, arbitration, mediation,
alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed
proceeding, whether brought in the right of the Company, a Subsidiary of the Company, or otherwise and whether of a civil (including
intentional or unintentional tort claims), criminal, administrative, or investigative or related nature, in which Indemnitee was,
is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director or officer of the
Company or a Subsidiary of the Company, by reason of any action (or failure to act) taken by him or of any action (or failure to
act) on his part while acting as a director or officer of the Company or a Subsidiary of the Company, or by reason of the fact that
he is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary,
employee or agent of any other Enterprise, in each case whether or not serving in such capacity at the time any liability or expense
is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.14. The term
&ldquo;<B><I>Subsidiary</I></B>,&rdquo; with respect to any Person, shall mean any corporation or other entity of which a majority
of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by that Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3. INDEMNITY
IN THIRD-PARTY PROCEEDINGS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the fullest extent permitted
by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this&nbsp;<U>Section&nbsp;3</U>&nbsp;if
Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding, other than
a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this&nbsp;<U>Section&nbsp;3</U>, Indemnitee
shall be indemnified, held harmless and exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in
settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments,
fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his behalf in connection with such
Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or
not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that his
conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4. INDEMNITY
IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the fullest extent permitted
by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this&nbsp;<U>Section&nbsp;4</U>&nbsp;if
Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding by or in the
right of the Company or a Subsidiary of the Company to procure a judgment in its favor. Pursuant to this&nbsp;<U>Section&nbsp;4</U>, Indemnitee
shall be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or on his behalf in connection
with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to
be in or not opposed to the best interests of the Company (including any Subsidiary). No indemnification, hold harmless or exoneration
for Expenses shall be made under this&nbsp;<U>Section&nbsp;4</U>&nbsp;in respect of any claim, issue or matter as to which Indemnitee
shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that any court in which the Proceeding
was brought or the Delaware Court shall determine upon application that, despite the adjudication of liability but in view of all the
circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification, to be held harmless or to exoneration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5. INDEMNIFICATION
FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provisions of this Agreement, to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise,
in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall, to the fullest extent permitted
by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him in connection
therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more
but less than all claims, issues or matters in such Proceeding, the Company shall, to the fullest extent permitted by applicable law,
indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection
with each successfully resolved claim, issue or matter. If the Indemnitee is not wholly successful in such Proceeding, the Company also
shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses reasonably
incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which the Indemnitee was successful. For
purposes of this&nbsp;<U>Section 5</U>&nbsp;and without limitation, the termination of any claim, issue or matter in such a Proceeding
by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6. INDEMNIFICATION
FOR EXPENSES OF A WITNESS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness in any Proceeding to which
Indemnitee is not a party, he shall, to the fullest extent permitted by applicable law, be indemnified, held harmless and exonerated against
all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7. ADDITIONAL
INDEMNIFICATION, HOLD HARMLESS AND EXONERATION RIGHTS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any limitation
in&nbsp;<U>Sections&nbsp;3</U>,&nbsp;<U>4</U>, or&nbsp;<U>5</U>, the Company shall, to the fullest extent permitted by applicable law,
indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including
a Proceeding by or in the right of the Company or a Subsidiary of the Company to procure a judgment in its favor) against all Expenses,
judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection
with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee
in connection with the Proceeding. No indemnification, hold harmless or exoneration rights shall be available under this&nbsp;<U>Section
7</U>&nbsp;on account of Indemnitee&rsquo;s conduct which constitutes a breach of Indemnitee&rsquo;s duty of loyalty to the Company, a
Company Subsidiary, or its or their stockholders, or is an act or omission not in good faith or which involves intentional misconduct
or a knowing violation of the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8. CONTRIBUTION
IN THE EVENT OF JOINT LIABILITY</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1.&nbsp; To the fullest
extent permissible under applicable law, if the indemnification, hold harmless and/or exoneration rights provided for in this Agreement
are unavailable to Indemnitee in whole or in part for any reason whatsoever, the Company, in lieu of indemnifying, holding harmless or
exonerating Indemnitee, shall pay, in the first instance, the entire amount incurred by Indemnitee, whether for judgments, liabilities,
fines, penalties, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee
to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have at any time against
Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2. The Company
shall not, without Indemnitee&rsquo;s consent, enter into any settlement of any Proceeding in which the Company is jointly liable with
Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted
against Indemnitee and no admission of guilt by, or injunctive relief against, Indemnitee, is included.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3. The Company
hereby agrees to fully indemnify, hold harmless and exonerate Indemnitee from any claims for contribution which may be brought by officers,
directors or employees of the Company other than Indemnitee who may be jointly liable with Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.
EXCLUSIONS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any provision
in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification, hold harmless or exoneration payment
in connection with any claim made against Indemnitee: &nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">for which payment has actually been received by or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount actually received under any insurance policy, contract, agreement, other indemnity provision or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act or similar provisions of state statutory law or common law; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">except as otherwise provided in&nbsp;<U>Sections&nbsp;14.5</U>&nbsp;and&nbsp;<U>14.6</U>&nbsp;hereof, prior to a Change in Control, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii)&nbsp;the Company provides the indemnification, hold harmless or exoneration payment, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10. ADVANCES
OF EXPENSES; DEFENSE OF CLAIM</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1. Notwithstanding
any provision of this Agreement to the contrary, and to the fullest extent not prohibited by applicable law, the Company shall pay the
Expenses incurred by Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee within three months) in connection
with any Proceeding within ten (10)&nbsp;days after the receipt by the Company of a statement or statements requesting such advances from
time to time, prior to the final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made
without regard to Indemnitee&rsquo;s ability to repay the Expenses and without regard to Indemnitee&rsquo;s ultimate entitlement to be
indemnified, held harmless or exonerated under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses
incurred pursuing a Proceeding to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to
the Company to support the advances claimed. If required by applicable law or the Charter or the Bylaws of the Company, such payments
of Expenses in advance of the final disposition of the Proceeding shall be made only upon the Company&rsquo;s receipt of an undertaking,
by or on behalf of the Indemnitee, to repay the advance to the extent that it is ultimately determined that Indemnitee is not entitled
to be indemnified by the Company under the provisions of this Agreement, the Charter, the Bylaws of the Company, applicable law or otherwise.
This&nbsp;<U>Section 10.1</U>&nbsp;shall not apply to any claim made by Indemnitee for which an indemnification, hold harmless or exoneration
payment is excluded pursuant to&nbsp;<U>Section&nbsp;9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2. The
Company will be entitled to participate in the Proceeding at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3. The Company
shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation
on the Indemnitee without the Indemnitee&rsquo;s prior written consent.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11. PROCEDURE FOR NOTIFICATION
AND APPLICATION FOR INDEMNIFICATION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1. Indemnitee
agrees to notify promptly the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information
or other document relating to any Proceeding or matter which may be subject to indemnification, hold harmless or exoneration rights, or
advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation
which it may have to the Indemnitee under this Agreement, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2. Indemnitee
may deliver to the Company a written application to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement.
Such application(s) may be delivered from time to time and at such time(s) as Indemnitee deems appropriate in his or her sole discretion.
Following such a written application for indemnification by Indemnitee, the Indemnitee&rsquo;s entitlement to indemnification shall be
determined according to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12. PROCEDURE
UPON APPLICATION FOR INDEMNIFICATION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.1. A determination,
if required by applicable law, with respect to Indemnitee&rsquo;s entitlement to indemnification shall be made in the specific case by
one of the following methods, which shall be at the election of Indemnitee: (i)&nbsp;by a majority vote of the Disinterested Directors,
even though less than a quorum of the Board; (ii)&nbsp;by Independent Counsel in a written opinion to the Board, a copy of which shall
be delivered to Indemnitee; or (iii) by vote of the stockholders. The Company promptly will advise Indemnitee in writing with respect
to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which
indemnification has been denied. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be
made within ten (10)&nbsp;days after such determination. Indemnitee shall reasonably cooperate with the person, persons or entity making
such determination with respect to Indemnitee&rsquo;s entitlement to indemnification, including providing to such person, persons or entity
upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which
is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys&rsquo;
fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be
borne by the Company (irrespective of the determination as to Indemnitee&rsquo;s entitlement to indemnification) and the Company hereby
indemnifies and agrees to hold Indemnitee harmless therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.2. In the event
the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to&nbsp;<U>Section 12.1</U>&nbsp;hereof,
the Independent Counsel shall be selected as provided in this&nbsp;<U>Section&nbsp;12.2</U>. The Independent Counsel shall be selected
by Indemnitee (unless Indemnitee shall request that such selection be made by the Board), and Indemnitee shall give written notice to
the Company advising it of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected
meets the requirements of &ldquo;Independent Counsel&rdquo; as defined in&nbsp;<U>Section&nbsp;2</U>&nbsp;of this Agreement. If the Independent
Counsel is selected by the Board, the Company shall give written notice to Indemnitee advising him of the identity of the Independent
Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of &ldquo;Independent Counsel&rdquo;
as defined in&nbsp;<U>Section&nbsp;2</U>&nbsp;of this Agreement. In either event, Indemnitee or the Company, as the case may be, may,
within ten (10)&nbsp;days after such written notice of selection shall have been received, deliver to the Company or to Indemnitee, as
the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that
the Independent Counsel so selected does not meet the requirements of &ldquo;Independent Counsel&rdquo; as defined in&nbsp;<U>Section&nbsp;2</U>&nbsp;of
this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection,
the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel
so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has
determined that such objection is without merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification
pursuant to&nbsp;<U>Section 11.2</U>&nbsp;hereof, no Independent Counsel shall have been selected and not objected to, either the Company
or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee
to the other&rsquo;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Delaware
Court, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel
under&nbsp;<U>Section 12.1</U>&nbsp;hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to&nbsp;<U>Section
14.1</U>&nbsp;of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject
to the applicable standards of professional conduct then prevailing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.3. The Company agrees
to pay the reasonable fees and expenses of Independent Counsel and to fully indemnify and hold harmless such Independent Counsel
against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement
pursuant hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13. PRESUMPTIONS
AND EFFECT OF CERTAIN PROCEEDINGS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1. In making a
determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall
presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification
in accordance with&nbsp;<U>Section 11.2</U>&nbsp;of this Agreement, and the Company shall have the burden of proof to overcome that presumption
in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure
of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action
pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct,
nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable
standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.2. If the person,
persons or entity empowered or selected under&nbsp;<U>Section&nbsp;12</U>&nbsp;of this Agreement to determine whether Indemnitee is entitled
to indemnification shall not have made a determination within thirty (30)&nbsp;days after receipt by the Company of the request therefor,
the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such
indemnification, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make
Indemnitee&rsquo;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a final judicial
determination that any or all such indemnification is expressly prohibited under applicable law; provided, however, that such 30-day period
may be extended for a reasonable time, not to exceed an additional fifteen (15)&nbsp;days, if the person, persons or entity making the
determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating
of documentation and/or information relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3. The termination
of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere
or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee
to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be
in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause
to believe that his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.4. For purposes
of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee&rsquo;s action is based on the
records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors
or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, its Board, any committee
of the Board or any director, or on information or records given or reports made to the Enterprise, its Board, any committee of the Board
or any director, by an independent certified public accountant or by an appraiser or other expert selected by the Enterprise, its Board,
any committee of the Board or any director. The provisions of this&nbsp;<U>Section 13.4</U>&nbsp;shall not be deemed to be exclusive or
to limit in any way the other circumstances in which the Indemnitee may be deemed or found to have met the applicable standard of conduct
set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5. The knowledge
and/or actions, or failure to act, of any other director, officer, trustee, partner, managing member, fiduciary, agent or employee of
the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14. REMEDIES
OF INDEMNITEE</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.1. In the event
that (i)&nbsp;a determination is made pursuant to&nbsp;<U>Section&nbsp;12</U>&nbsp;of this Agreement that Indemnitee is not entitled to
indemnification under this Agreement, (ii)&nbsp;advancement of Expenses, to the fullest extent permitted by applicable law, is not timely
made pursuant to&nbsp;<U>Section 10</U>&nbsp;of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have
been made pursuant to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement within thirty (30)&nbsp;days after receipt by the Company of the
request for indemnification, (iv)&nbsp;payment of indemnification is not made pursuant to&nbsp;<U>Sections&nbsp;5</U>,&nbsp;<U>6</U>,&nbsp;<U>7</U>&nbsp;or
the last sentence of&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement within ten (10)&nbsp;days after receipt by the Company of a written
request therefor, (v)&nbsp;a contribution payment is not made in a timely manner pursuant to&nbsp;<U>Section&nbsp;8</U>&nbsp;of this Agreement,
(vi)&nbsp;payment of indemnification pursuant to&nbsp;<U>Section 3</U>&nbsp;or&nbsp;<U>4</U>&nbsp;of this Agreement is not made within
ten (10)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification, or (vii)&nbsp;payment to Indemnitee
pursuant to any hold harmless or exoneration rights under this Agreement or otherwise is not made within ten (10)&nbsp;days after receipt
by the Company of a written request therefor, Indemnitee shall be entitled to an adjudication by the Delaware Court to such indemnification,
hold harmless, exoneration, contribution or advancement rights. Alternatively, Indemnitee, at his option, may seek an award in arbitration
to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Except as
set forth herein, the provisions of Delaware law (without regard to its conflict of laws rules) shall apply to any such arbitration. The
Company shall not oppose Indemnitee&rsquo;s right to seek any such adjudication or award in arbitration.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.2. In the event
that a determination shall have been made pursuant to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement that Indemnitee is not entitled
to indemnification, any judicial proceeding or arbitration commenced pursuant to this&nbsp;<U>Section&nbsp;14</U>&nbsp;shall be conducted
in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.
In any judicial proceeding or arbitration commenced pursuant to this&nbsp;<U>Section&nbsp;14</U>, Indemnitee shall be presumed to be entitled
to be indemnified, held harmless, exonerated to receive advances of Expenses under this Agreement and the Company shall have the burden
of proving Indemnitee is not entitled to be indemnified, held harmless, exonerated and to receive advances of Expenses, as the case may
be, and the Company may not refer to or introduce into evidence any determination pursuant to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement
adverse to Indemnitee for any purpose. If Indemnitee commences a judicial proceeding or arbitration pursuant to this&nbsp;<U>Section&nbsp;14</U>,
Indemnitee shall not be required to reimburse the Company for any advances pursuant to&nbsp;<U>Section&nbsp;10</U>&nbsp;until a final
determination is made with respect to Indemnitee&rsquo;s entitlement to indemnification (as to which all rights of appeal have been exhausted
or lapsed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.3. If a determination
shall have been made pursuant to&nbsp;<U>Section 12.1</U>&nbsp;of this Agreement that Indemnitee is entitled to indemnification, the
Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to
this&nbsp;<U>Section&nbsp;14</U>, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact
necessary to make Indemnitee&rsquo;s statement not materially misleading, in connection with the request for indemnification, or
(ii)&nbsp;a prohibition of such indemnification under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.4. The Company
shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this&nbsp;<U>Section&nbsp;14</U>&nbsp;that
the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before
any such arbitrator that the Company is bound by all the provisions of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.5. The Company
shall indemnify and hold harmless Indemnitee to the fullest extent permitted by law against all Expenses and, if requested by Indemnitee,
shall (within ten (10)&nbsp;days after the Company&rsquo;s receipt of such written request) pay to Indemnitee, to the fullest extent permitted
by applicable law, such Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought by
Indemnitee (i)&nbsp;to enforce his rights under, or to recover damages for breach of, this Agreement or any other indemnification, hold
harmless, exoneration, advancement or contribution agreement or provision of the Charter, or the Company&rsquo;s Bylaws now or hereafter
in effect; or (ii)&nbsp;for recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless
of the outcome and whether Indemnitee ultimately is determined to be entitled to such indemnification, hold harmless or exoneration right,
advancement, contribution or insurance recovery, as the case may be (unless such judicial proceeding or arbitration was not brought by
Indemnitee in good faith).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.6. Interest shall
be paid by the Company to Indemnitee at the legal rate under Delaware law for amounts which the Company indemnifies, holds harmless or
exonerates, or is obliged to indemnify, hold harmless or exonerate for the period commencing with the date on which Indemnitee requests
indemnification, to be held harmless, exonerated, contribution, reimbursement or advancement of any Expenses and ending with the date
on which such payment is made to Indemnitee by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15. SECURITY</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, to the extent requested by the Indemnitee, the Company may at any time and from time to time provide security to the
Indemnitee for the Company&rsquo;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.
Any such security, once provided to the Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16. NON-EXCLUSIVITY;
SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.1. The rights
of Indemnitee as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled
under applicable law, the Charter, the Company&rsquo;s Bylaws, any organizational documents of any Company Subsidiary, any agreement,
a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision
hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any Proceeding (regardless of when such Proceeding
is first threatened, commenced or completed) arising out of, or related to, any action taken or omitted by such Indemnitee in his Corporate
Status prior to such amendment, alteration or repeal. To the extent that a change in applicable law, whether by statute or judicial decision,
permits greater indemnification, hold harmless or exoneration rights or advancement of Expenses than would be afforded currently under
the Charter, the Company&rsquo;s Bylaws, any organizational documents of any Company Subsidiary, or this Agreement, then this Agreement
(without any further action by the parties hereto) shall automatically be deemed to be amended to require that the Company indemnify Indemnitee
to the fullest extent permitted by law. No right or remedy herein conferred is intended to be exclusive of any other right or remedy,
and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter
existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent
the concurrent assertion or employment of any other right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.2. The DGCL, the
Charter and the Company&rsquo;s Bylaws permit the Company to purchase and maintain insurance or furnish similar protection or make other
arrangements including, but not limited to, providing a trust fund, letter of credit, or surety bond (&ldquo;<B><I>Indemnification Arrangements</I></B>&rdquo;)
on behalf of Indemnitee against any liability asserted against him or incurred by or on behalf of him or in such capacity as a director,
officer, employee or agent of the Company, or arising out of his status as such, whether or not the Company would have the power to indemnify
him against such liability under the provisions of this Agreement or under the DGCL, as it may then be in effect. The purchase, establishment,
and maintenance of any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations of the Company
or of the Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the
Company and the Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other party or parties
thereto under any such Indemnification Arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.3.&nbsp; To the extent
that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, trustees, partners,
managing members, fiduciaries, employees, or agents of the Company or of any other Enterprise which such person serves at the request
of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of
the coverage available for any such director, officer, trustee, partner, managing member, fiduciary, employee or agent under such policy
or policies. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a participant
(as a witness or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice
of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter
take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of
such Proceeding in accordance with the terms of such policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.4. In the event
of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of
Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents
as are necessary to enable the Company to bring suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.5. The
Company&rsquo;s obligation to indemnify, hold harmless, exonerate or advance Expenses hereunder to Indemnitee who is or was serving
at the request of the Company as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other
Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification, hold harmless or exoneration payments
or advancement of expenses from such Enterprise. Notwithstanding any other provision of this Agreement to the contrary,
(i)&nbsp;Indemnitee shall have no obligation to reduce, offset, allocate, pursue or apportion any indemnification, hold harmless,
exoneration, advancement, contribution or insurance coverage among multiple parties possessing such duties to Indemnitee prior to
the Company&rsquo;s satisfaction and performance of all its obligations under this Agreement, and (ii)&nbsp;the Company shall
perform fully its obligations under this Agreement without regard to whether Indemnitee holds, may pursue or has pursued any
indemnification, advancement, hold harmless, exoneration, contribution or insurance coverage rights against any person or entity
other than the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17. DURATION
OF AGREEMENT</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All agreements and obligations
of the Company contained herein shall continue during the period Indemnitee serves as a director or officer of the Company or as a director,
officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, partnership, joint venture, trust,
employee benefit plan or other Enterprise which Indemnitee serves at the request of the Company and shall continue thereafter so long
as Indemnitee shall be subject to any possible Proceeding (including any rights of appeal thereto and any Proceeding commenced by Indemnitee
pursuant to&nbsp;<U>Section&nbsp;14</U>&nbsp;of this Agreement) by reason of his Corporate Status, whether or not he is acting in any
such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18. SEVERABILITY</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any provision or provisions
of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and
enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or
sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal
or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by
law; (b)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the
maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement (including,
without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid,
illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent
manifested thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>19. ENFORCEMENT
AND BINDING EFFECT</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.1. The Company
expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce
Indemnitee to serve as a director, officer or key employee of the Company, and the Company acknowledges that Indemnitee is relying upon
this Agreement in serving as a director, officer or key employee of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.2. Without limiting
any of the rights of Indemnitee under the Charter or Bylaws of the Company as they may be amended from time to time, this Agreement constitutes
the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings,
oral, written and implied, between the parties hereto with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.3. The indemnification,
hold harmless, exoneration and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon
and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase,
merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee
who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise at the Company&rsquo;s request,
and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal
representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.4. The Company shall
require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all
or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to the Indemnitee,
expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to
perform if no such succession had taken place.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.5. The Company
and Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable
and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree
that Indemnitee may enforce this Agreement by seeking, among other things, injunctive relief and/or specific performance hereof, without
any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee
shall not be precluded from seeking or obtaining any other relief to which he may be entitled. The Company and Indemnitee further agree
that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary
injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company
acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a Court of competent jurisdiction
and the Company hereby waives any such requirement of such a bond or undertaking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20. MODIFICATION
AND WAIVER</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No supplement, modification
or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of
this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute
a continuing waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21. NOTICES</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices, requests, demands
and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i)&nbsp;if delivered by
hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii)&nbsp;mailed by certified
or registered mail with postage prepaid, on the third (3rd) business day after the date on which it is so mailed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If to Indemnitee, at the address
indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide in writing to the Company.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If to the Company, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">180 Life Sciences Corp.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3000 El Camino Real, Bldg. 4, Suite 200<BR>
Palo Alto, CA 94306</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">With a copy, which shall not constitute notice, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Loev Law Firm, PC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: David M. Loev</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6300 West Loop South, Suite 280</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bellaire, Texas 77401</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: (713) 524-4122</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: dloev@loevlaw.com</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">or to any other address as may have been furnished to Indemnitee in writing by the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>22. APPLICABLE
LAW AND CONSENT TO JURISDICTION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement and the legal
relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without
regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to&nbsp;<U>Section 14.1</U>&nbsp;of
this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally: (a)&nbsp;agree that any action or proceeding arising
out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or federal court in
the United States of America or any court in any other country; (b) consent to submit to the exclusive jurisdiction of the Delaware Court
for purposes of any action or proceeding arising out of or in connection with this Agreement; (c)&nbsp;waive any objection to the laying
of venue of any such action or proceeding in the Delaware Court; and (d)&nbsp;waive, and agree not to plead or to make, any claim that
any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum, or is subject (in whole
or in part) to a jury trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>23. IDENTICAL
COUNTERPARTS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be executed
in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute
one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to
evidence the existence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>24. MISCELLANEOUS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Use of the masculine pronoun
shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted
for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>25. PERIOD
OF LIMITATIONS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No legal action shall be brought
and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee&rsquo;s spouse, heirs, executors
or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim
or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within
such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action
such shorter period shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>26. ADDITIONAL
ACTS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If for the validation of any
of the provisions in this Agreement any act, resolution, approval or other procedure is required, the Company undertakes to cause such
act, resolution, approval or other procedure to be affected or adopted in a manner that will enable the Company to fulfill its obligations
under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto have
caused this Indemnity Agreement to be signed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>180 LIFE SCIENCES CORP.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Blair Jordan</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:<U>Blair Jordan</U></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: <U>Interim CEO</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><B>SIR MARC FELDMANN</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>/s/ Sir Marc Feldmann</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">Sir Marc Feldmann</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">XXXXXXXXXXXX</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">XXXXXXXXXXXX</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">UK</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page 14 of 14</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>atnf-20240905.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 86o5s7xRiXhun8uDb31cWa6D2aPty5BxuZkxsmxxHWl6HyIntqFCJiijIxFWQQ8B -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ATNF="http://180lifesciences.com/20240905" elementFormDefault="qualified" targetNamespace="http://180lifesciences.com/20240905">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://180lifesciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240905_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240905_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="atnf-20240905_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>atnf-20240905_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20240905.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240905.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240905.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>atnf-20240905_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20240905.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20240905.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>atnf-20240905_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20240905.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240905.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20240905.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140453053075248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  05,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180
LIFE SCIENCES CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">&#160;Bldg. 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">&#160;Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *>#*5D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "G@RE9^<E*>.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2@,Q$(=?17+?G>Q6A(9M+A5/"H(%Q5M(IFUP\X=D9+=O;W9MMX@^@)!+9G[Y
MYAM(IZ/0(>%S"A$36<PWH^M]%CINV)$H"H"LC^A4KDO"E^8^)*>H7-,!HM(?
MZH#0<GX'#DD910HF8!47(I.=T4(G5!32&6_T@H^?J9]A1@/VZ-!3AJ9N@,EI
M8CR-?0=7P 0C3"Y_%] LQ+GZ)W;N #LGQVR7U# ,];":<V6'!MZ>'E_F=2OK
M,RFOL;S*5M IXH9=)K^NMO>[!R9;WMY6?%W.KN6B78N&OT^N/_RNPBX8N[?_
MV/@B*#OX]2_D%U!+ P04    " "G@RE9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M *>#*5EO3[U]Q 0  *H4   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9A=<^HV$(;O^RLT/IU..Y. ;#X"*3!#"&F9DY/0F#8SO1.V $ULRT>20_+O
MNS+$)CEF37,#MK%>'N^N]I4UV$KUI#><&_(21XD>.AMCTLMF4P<;'C/=D"E/
MX)>55#$S<*K639TJSL)\4!PU/4J[S9B)Q!D-\FMS-1K(S$0BX7-%=!;'3+U>
M\4ANAX[KO%UX$.N-L1>:HT'*UMSGYN]TKN"L6:B$(N:)%C(ABJ^&SMB]O&I1
M.R"_XQ_!M_K@F-A'64KY9$]FX="AEHA'/#!6@L'7,Y_P*+)*P/%]+^H4_VD'
M'AZ_J=_D#P\/LV2:3V3T*$*S&3H]AX1\Q;+(/,CMGWS_0!VK%\A(YY]DN[NW
MW79(D&DCX_U@((A%LOMF+_M G#+ VP_P<N[='^64U\RPT4#)+5'V;E"S!_FC
MYJ,!3B0V*[Y1\*N <68TD<]<#9H&I.R%9K ?=K4;YAT9YO.T06CGC'C4:[\?
MW@2" L,K,+Q<KW5$[UH&&>3:D,5KRJMP\.&]\Z\(1*N :*$J8R (<XJ;B*VK
M*/#Q*Q9ICG"T"X[V:<&8<R5D2*9)2""YE7'!E?(TY7FJ2U2G8.N@BM/$"/-*
M;D3$R5T6+ZN+!]>@U#UO]5S:07BZ!4_W%)X'OA;:* 9!NV-Q9:1P';='?[J=
MW4R)/YE-[R93GTSN'^8-A/"B(+PXA7 ""54L(K,DY"_D*W^M8L25* 2NVZ>T
M1Q&L7H'5.P5KP5[(+ 0VL1(!RQOE\;3BBGUZ[O;ZM-7!ZJQ?X/5/P9LE@52I
M5#G9&?$-3 ,B%9G(#,()495A9;)Q\>LI0NC2LG724QC'8:BXUF=O!^06[B/W
M2258C60+<DRF$9DPZ/42RII%&.I!EW<_C[K8RDI45-(N%RYUR@(^=& ]H+EZ
MYL[HER]NE_Y^%87K!L'*P"V-P<5;.TZ^4;PZS*@HQNYG DH,%C48?>DH+FX)
M'^DG]@SJ=R&W224W+C=GD23CR$@,KK09%W>'CW#%[)HK^2R2H#JRN.9DC*&5
M+N.>9#,%VEQJ \WS7Y$>G?(UBOUVBW8QMM)Q7-PJ\AR.80E\' 47Z';0XBJ-
MQ<7]X%8&$)/Y1B:8%]>(=.C%.>UV^QA1Z2DN;@&/2AC#$PA,'&?)WE!T)14N
M5+>4<DL?<?%>[\M(!,*(9$V^07DK\;&C[GEPE3H>KS0-#^_P<\7/ P@/A_FU
M6_'"HI,K<K]:5>>O1J^6K/0(#_>('\AF6F= 5@N(R]8"'KPCG&0%TYBKM<WG
M'Z!@-K;84I94KJ=J!&O1RC[OX8W9%CPLG7PC@Z<SDC)%GEF4<?(S;=A5&TDA
M@'K#5/6[#:J-F17&7MJ A[?LA3"PF)<KXGJ_+G\C/@\RF,;5\:QI_I^+PGON
MTB,\O*,O% MM&?BO\5)63NH:@?'B[@8C*1W!PQOZ6\C(]"78L&3-C[Z$U C=
MC?WK\5\84VD.'M[7'YFRKT.:&$G23 &7YKO@:YOKPU15@J+JGZW)TD@\O/__
MGYJLL:3/QN$]>>DW'NX4)U0E+F"K\A';S2BMIH5;P^EE62-TO"R;!SM/=A?O
M&[.M69.(KT")-BY@!JK=QMCNQ,@TWXQ:2F-DG!]N. -_L3? [RLIS=N)W=\J
MMB='_P%02P,$%     @ IX,I6>#T.HFJ @  , P   T   !X;"]S='EL97,N
M>&UL[5?;BMLP$/T5H0^HD[@U<4D";2!0:,O"[D-?E5AV!+JXLIPZ^_756+9S
M6<WV\ECJD'AFCF;FC&9DDU7CSI(_'CEWI%-2-VMZ=*Y^GR3-X<@5:]Z8FFN/
ME,8JYKQJJZ2I+6=% TY*)HO9+$L4$YIN5KI5.^4:<C"M=FLZH\EF51I]L:0T
M&/Q2IC@Y,;FF6R;%WHI^+5-"GH-Y 8:#D<82YZGP-9V#I7D.\#QHP'*(HX0V
M%HQ)R!!^]\/R.V#4&J\**2>""QH,FU7-G.-6[[S2+^Z-+R RR$_GVC.L+#O/
M%^_HQ:&_^21[8PMNIS1S.IHV*\E+H&-%=82[,W4"H'-&>:$0K#*:]1Q&CT'P
M80]<RD=HX;?R)G97DM"+3P6T@4"IH^@)#6(($Q2(?QTMQ+X*^_:OPI):G(S[
MV/IJ=*]_;XWC#Y:7HNOUKISR8]'G>'16U_+\08I**QYJ_^V$FQ4;_<C16/'L
ML\&D'+R!6TI.W#IQN+;\L*Q^XIT;IZDK<<Z+_YQ_P;GBFELFKTG[T8\S3H99
MO!KXFW&?K 0>*VOZ%9Y6\L*![%LAG="#=A1%P?6+J??A'=O[Q^%-?+^^X"5K
MI7N:P#6]R%]X(5J53ZL>8%^&51?Y,YSN>38]TWPNH0O>\6([J+;:]R+Q@L\Z
M7.!PC^SZ*XY@/@&+(X!A>3 &F$_PPO+\2_4LT7H"AG%;1I$EZK-$?8)7#-GV
M'RQ/W"?W5[S2/$_3+,-V=+N-,MAB^Y9E\(U'P[B!!Y8',OW97N/=QB?D]3G
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M;%!+ 0(4 Q0    ( *>#*5GYR4IX[@   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *>#*5F97)PC$ 8  )PG
M   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ IX,I66]/O7W$!   JA0  !@              ("!#0@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *>#*5G@]#J)J@(  # ,
M   -              "  0<-  !X;"]S='EL97,N>&UL4$L! A0#%     @
MIX,I69>*NQS     $P(   L              ( !W \  %]R96QS+RYR96QS
M4$L! A0#%     @ IX,I6:K$(A8S 0  (@(   \              ( !Q1
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *>#*5DD'INBK0   /@!   :
M              "  242  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( *>#*5EED'F2&0$  ,\#   3              "  0H3  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  %04      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0213868-8k_180life.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180lifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnf-20240905.xsd</File>
    <File>atnf-20240905_def.xml</File>
    <File>atnf-20240905_lab.xml</File>
    <File>atnf-20240905_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0213868-8k_180life.htm">ea0213868-8k_180life.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0213868-8k_180life.htm": {
   "nsprefix": "ATNF",
   "nsuri": "http://180lifesciences.com/20240905",
   "dts": {
    "schema": {
     "local": [
      "atnf-20240905.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "atnf-20240905_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20240905_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20240905_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0213868-8k_180life.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://180lifesciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0213868-8k_180life.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0213868-8k_180life.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "auth_ref": []
    },
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20240905",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://180lifesciences.com/20240905",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001213900-24-076949-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-076949-xbrl.zip
M4$L#!!0    ( *>#*5F W_%QSP,  .H.   1    871N9BTR,#(T,#DP-2YX
M<V2]5UMWVC@0?M]S^A^T?O<%*-G$A?:TX="R)VEI2)N>OO0(6P9M;,F5Y.#\
M^QW)EP &%]A->9)'WS<7:68T#-[D28P>B)"4LZ'5<3P+$1;PD++%T/HRL]_.
M+B<3"[UY_>(/!+_!G[:-QI3$H8]&/+ G+.*OT$><$!^])XP(K+AXA;[B.-,2
M/J8Q$>B2)VE,%(&-PI*/^DZW-T>V?8#>KX2%7'RYF=1ZETJETG?=U6KE,/Z
M5US<2R?@R6$*9PJK3-;:O-PK?X?1KZD,:O+Y&>_+O_(;^FV9L?-L-.]U@CM\
M-NKBJ7KLO\NS[_>Y3/+\PUU\]N%QPM3/\>7?E/XSR<=WGS^?ORM,#F2P) E&
M<!E,#BT=7QG>JN=PL7"[GM=QOUU?S0S.*H!^'E-VOPO>N;BX<,UN!6T@\[F(
M*]4]5V_/L22U9MBE+7C*I,(LV,"'JB:L@_MNL;D!I3NA9P645M"0;.$D"9P%
M?W!A _#=EQ4PD_8"X[0&1UC.C=)R8P,LA6H"0;@-LM5C2N1.:+&U00B5V")L
MG!ILNWI;<[JVU[-[G8KY]O;CN"9USKV81D0&%,J0F*0V9KP+KP^E&9.$,#7F
M(AF1"&<Q1/(SP\"@)+20PF)!E,Y2F>* '*:TRGC,&(?"@.HL)5J6IA0ROQ:
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M0$(@IN2,3T+AKW3Z&"'1P630EDIS1 GWMGZ@,?(<&PC8V;W*P".Q?[+DC[T
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M4<Y[S111.[-*[5L(W$W69H=6C>;;"A;DV5&B&X-*;WTP91;BE7&=MVP!WQ;
M(.>.$MP8V$C#%XB.68"WO^%=&>D'IBU@W888I-U18ALCFPBR1F(W)7YUQW)H
MVP+BK9!!YAUELS&T&=J. QT$69!X#6NU (!+"W0H0P[*X2B=C1&.F<_%AF?N
M=X]XJ*_:W8@'I4- J6,+I*G&#PKD*.>-<0Z#0& IDS\FKD&9+!;S%H@!H08?
M@#G*?R%TI\=)<-I*"4[+)7"4_T+HSHZ3X*R5$IR52^ H"\ZA&^G#6S'C3\#3
M=\"X/?0?8 ;)=YH")]BB:&[%1/!'$F\)JE+@P*,],MB @UHX39/3=A)/%^I<
M!;%E>[C/ @8Y=YHF)\ F7"I$_T<V5;-3FWU[^"_"!E5PE#4G+<+<1H&67>5,
M&LUU$2E(KZ/4V(PY0X$1W*RS%LTF]Q HR*VC//<+-T]U5IR5WD,^M&HTQU:P
M(,^NTE6S%4^"W</^ZT8SFT<)4?KB;0Y'4OI#$*7QF)7D(4ON( %/_JRFC:8:
M1@S2[BCEG')*?,T06W[5<0B"J)WSHEVC"0?@@FP[RBXG ILV8+;H1HOAS'Y>
M<;M80#TU;-]H]BM@@RHX2C,/X(VE#+$X5HN"5YL4L8,'=7&4<DZQ'^J.<C<X
MG<_,1G6@)SJP:C3O5K @SX[2S&]\)I!YR\YTMYYS"F_AL1@VFFT(+TBXHXPR
MA\I.=<ZDT207D8+T.LHHTXOL>NNO$%MB>$6'S;+19(. 0<X=99K/'=NR5E^]
M;%-?O:S15SO*-%-0\4)]?=W=SBE9(GA'8(E#*]B'<$-"V&)Z"R'B_5KFW6UB
M':&ZT0=V":RFC28?1@S2[FHK;!@0A8,8X UAB/DZF=L'!=PAJ/)JMAAUP(.Z
M.'U.^@-3^AOC3VR*D>0,!W%B4?:T G!IM"+5R$$YG#XY_<YIR!02T9); 5P;
M5M,6T&]##-+N]"%ILJQ\/W+%+_4L8]_NT0(12H"#6CA]>#IF"@OD*_*(/R.%
M$KQE6M@]6J!%"7!0"Z<+CZ,+=:3C6?+RM0,YPQ8P7\0+$NYTO?%TC2C]%$H=
M@"SM?W*&+2"\B!<DW.F*XNLU%DO=#?XJ^)-:)1MYRXBW.K1  !@W*(33E</7
MV^<7"\2[&DM5*%BW00([:(C_<\?;9H>^;Y::Q',"%B !* #;-UJ#"MB@"H[2
MY%NUPB([*XN@F6#*%H)4>35:D5K@05V<ILG9USR4#LL9NT9S#\ %V7::!4_"
M.27^#>6H=-Z?,6L!UX=H0:J=9KZ?$'L0X4;YNXG@/L;FP9#<7Y,UDJ]:!;1
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M(K;J5^ DP]DF+4L[W![F?W3XZR2F#Z?RKQE."1+GBZ:GVS1^,Y#'S0_[='S
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M:([[0G,<-#3'+X)&-+S7ON9<?+SE4_9D>S@;5'I!IFG5"LQ.%AXN#6]=L,@
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M0P@@S9WT\ZXYFKQ9WM,Q56ZQQ9 NS!O;T$-X*@4H#@U4/=X)!>91$J]7K8)
MV^2#_7;]C?OA_KJ!/?(/4$L#!!0    ( *>#*5E-2E2:HQ@  )J4   8
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M ^B\]L<P;@@]K8Y ]"LJ326D-'6F49 NS+#1&B)_5;O9PZ/">4%YN;O.+BO
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M5PUP^V640_#VJP5\ 7AS0C6JV&#NNL$KRF.(U; 5T.-N8<.KO1FO,CO7_>$
M<Y739HA\PD #T77HP"H8N4D?F 7]P(G(NH+K\++"K[S&QGBONBJ;JD7XYC6$
M'UG.SF[)X7)VT#NDG3>^6FQN"%#O_9%F&[J)+7#36F2-,7!3V[NZB2THHX!T
M7G$@7H6?@$!1E'L Z7Z,JV" D,N51Y[+(_Q(H3BX8HMW=BPMV19X;K' GHY^
M55N)RZCUFA66B9W[#-TK&9?8,JE\E^I2L'Y@?<1%$819B(#I7DCB,Q*0?M"#
M!C$&]?=55/?5M*I;;D" #YH@B*2&=R/@-F&#R,3;644.,?)B>-HB4>F;E&<#
MZ8WMP'Y](2QL#!;2>:9#--/KH=M_H 2K H$+@A(856P3<5<@IZP'P:+[0P"D
M:IBCM'_\8 OG!_PF><'/"F<+JE[(Y #QLPJ (NY]@'G6T+19RL#SC,0:=RVF
M,MF$J;4JZWJ7@0E,21/2H*%,3FTUO0VC>)D^22<"1\$Q=GTF33[L17)@TN2S
M8-6;X;E-\QB=:Q!(37:Q8M,6S.E8<_&5R)FDV\S$7$DA=3 O&$!].^%L*#<A
MD #8J?EAG^I 9L"<OR'=1QSL,&"TMW1 R.0E'I^3;9]V"/1-)$5E)@RWL=@N
MP9>GR 0B$GGH;YY7-!ET:P9# .]DGQWJJ\S2A5)D:P[!(?>YPQ 0IB_ A0'9
M:-;Q.K%EE"5>!O8I+\O T9:JERCB8SY&##>P<.7R](KD=[:STFZ@YJ<X-3^+
MY^NH$<;(V382+!%*PC8>68[IY<290+<YQ&L7[(E!\!HRBX/#:'A*304B3X@L
M00VQ^[_%=#$_7\=RM$'1#(M'HK)&K7G; &N^8PFA7_!-7->V$_-M+8N=(90U
M@+"*J\N.6?)[=51R,=19=VSAU1%XK0"H<5,##O"PB'LZ1!YBQ Q"F#@R#DD7
M$G. #2Z).D.4P(#<HN8#GL\#EB  =\Z:F'Q3D0-A;FII\L0XA['Y@;I,G(H0
M^$'2=X^7F*ZG"2%(++FKD.+ RX 7#8 /  M2L(T.^#O8.W<(U+1EAJ.M4$>%
M' \3(AFR3<-5T$2@#PBMY]P3#\9@ UF03*949J%*C%$_\+OE;"3F,O%;H)#Z
MKG 0FV(8(U?X\/F!ZKS<#2AZ\H/CV18X3@3%WQGXY7#X!U@9.1D8D-JECCFI
M87TK.OJVX6)'E$MX*U=4P2&DD9%!PK.^D)##,Z).\)=2P,S\*SLBYD)?7] )
M.6K(<UNVT'71_KC1)[P[K0C\28.=&WB2RRVX@8,!$7 CM6P?9Y2;.)A!=\MA
M)9YDU]RX2=^/&6J./9!M[)7P!+#%/OB4S\($]TQCZ+C)OHR_;08&HG&UTRWJ
M^$^-R5VF.84X3BN@&+DF!Z)1P)*0)_SJS-,A^$-YE@#-]<RTBV3*EG.<+=C0
MY]IU5@ANT34P,"0_X$)RW#:]L:;Q.S*G7*#RV!X8)F3"*E[/ \8XQ.,X:@)P
M!P>&@]QB(!I9?<"?= NSSG0>E:A(<H2+U=URA#]Z3'\ &MS#>MM8*44XX*"H
M;6O.4 $U\FA$90TG*61J+C['=T2 #C=#CJD.BJC0:.F9K#\ *<WGGEC%^8,<
M1L<)3&G?X+/[>,CG*<<3)Z*F.3X8\2:'9?(Y&%USM=,B]V,@Q[N?$;45)Q23
MVC-'[]T?0_+4-@IS(A"B?H@B UW'B#DQD&-NJ,ZR;<O* /""CZ'HY*Q@P7>%
MP+8V'; N4BP*:3&TCH(TK P&>DO>=1V>GP ?K<WXO(^4,O]*+,\A8\W^F=3Z
MR7*(TI",80! QF BWA#\2G'YO"*PBQ4!YX:Q&MX ;*TSYW\[BWSA<BO,_3V8
MRGFR@;$0]]IN1!63&BQ.T!C3C2TL0LM=B,["@0+6O,5M02IL%[.QR88;A&'D
M9HQM7K4&M^)JXKJT;,WWE,^A!@7_V(W>7/N*J'UUOUCO+T-;W)P]GY%>XU6Z
M&]7,!27$&]4#/&R"\%?9XO[Z.]DC[=SE*'RHR+\/R)?]:+U'?;K>U(47[ZVX
MR3OB;A.?"T^TD73_U!;P:/D(K[$A_)!:BLE&WC42KL1><W_W"I+?I)I@5//?
MG]2,9ZG#R_B5B?,[FU06)#&[6]@51#H5A93H_=YM>F /U[]'+2[B<GXQ]<D"
MLLICN>5J*[:N,Q,2,_\W49V%W)?!V\8@&GMTJ3VA5(^MM\<L"OBUH%"=FRSN
M+Y-CC6'EK:=OK^S2,Y1]U6.>/V4!/X,DUBRDMS0+-R^#W"Y><[,!2WAD76+;
M5^EGJ>[/:.XOX+%SOY,*KTTN54A:3+[;@#0P4I =G3J4;=FY?GD+54O%JCG6
MCYPT&)IBXDRN#UJG1'5_?L7"I:IW=)_=1G^.\9D_"/7/<?SR?U<Z1(XJYU2=
M4-O24>>RWUTVF%QA^XZT1RZ<-:020G4WG^T1?ICFM]S=$Q"&)X8]@C^+5R(5
M4^XR98__*(TCJG,#!2"&=N1XO?AVM]]UK]![O'83'%BBW3@ZKW0N6^OY(=#W
M>ROC<AWG$8*:[O;1A%MP=Q?(^.2WXB[S[:AML>I8FQ%%'F,5D>\X=WZ6S5VD
MM8!B9Y$6Z^E=.I"U'J8NN-C :]AN W2:8RR <W#S1:OU%:I?:Z0>_56[TO):
M]2LS^+[OF5CEAN/H*!4@8?CV*9E=<[F(9R%1OZ?VDGK1/+-XDHG ^W7 7J-0
M#F:ER&S$IUY*KAH$K'6L6#EC91 'Y(;'@%C6G7V:+Q^DA?BP(#Q^\X5W[_M*
MK?)_K9-Y'HUX2.,S1>_F#7&MR,,B7Z]-;%B7^4G<2'5>(Q*>F[)AW$;0W^4P
MWL;PO#B.ES:8)*WE1$LP'7KC,RL+PQ3*@&POW9FJTSW2..0?;H7=@UN^R\BY
M6AO)X-WH\52\4^L7D[O*EU;W8Z67[PO-T<G,O#H1ND6C?W;3D(23ZD,[KY\,
M=%D?J@+K'1]G"M<WIW=?>FKW].3;C^/ISH[4/KPY&)P5+K6OL^;A='P\./BN
M?^VT;\:3R4'CFWI3'S=T\6-;J1:KF>GEU#R]%$>J?E:]_FP<-8]NKF=%M2]D
MQIIR=#X9-C[FCW*?E<MLXR+7/KOY9GWNSPJ]N_O"UX.'RZ_6W<GH/%^9VNW)
M%_:0EZH/=[MW5;EP?Y&]8K5NJW-_<'+0*GZ<VJRF7$_:^D.^U9W\.#L>:Y.K
M0^/'K'IS9EZ=#_.&<GIQ?S&H#>MV]^Q'LR?N]+[=L_-OW?M\79S9^1_')U?C
MO%2[/YP5Q+OSHX_:U4YM^-!M7>Y<?+LQ\S6UWKC+?;<ZAR?*QV\'EP]?]*/^
MY'-?N3=:2L7,5#_OYKY^/-;OM/OIM_I)H]TX&[9[N5;FNEV\&YP?'P^R._6)
MJ#:_C"\RTX92H,VL<JWU)Y^<$<IT#76&?P?V4"O_/U!+ P04    " "G@RE9
MFRSG*#1'   79P$ '0   &5A,#(Q,S@V.# Q97@Q,"TQ7S$X,&QI9F4N:'1M
M[7UY;]M8EN__ O0=^((W!1= *UZR)Q/ <9PN]Z22P':Z,!@,'BCR2F*%(E5<
M[*@__3O;W4A*LA,[<<IIH"NR1-[UW'//^CLO?CO[_>W+X>#%;T<'K^'? /_W
MXNSX[.W1RQ?W^5_X];[\_.+5^]?_'9R>_??;H_^\-RGR^EFPN[.H@[-TKJK@
MG;H(3HIYE(?\11B<JC*=W(,7X=4/5WWO>3"/RFF:/POPT9WG0:T^U]M1ED[A
MJS*=SNI[+U^\>GGT>9:.TQH:'.V^N/\*AOWA)CJ,55ZK\M[+7_)QM7A^PYW
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M$:!9NYI$L6N4=SIOR7%SVGM7^G)CJ(8#LE#ZT4]:&UDM(&2I^"%\<[%69[^
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M_#17'(Z-,<'Y-D?CH[!IMX%6@6T%)@5?=X^<M0:I:T$2IT$9I.NB E*)9Y)
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M=$+<R<HE8 2;ZQL(?A=KR@13;Z/U1$4W(>^4[V\*4VIS&M8A):19*EB13SF
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M+@F!>6UTIHGB2"3+5;NC\7WB>D4IP \<LT8!'-K/1.$!&"P+JS+/,964?BY
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M-EIIXHJQB^L;<XB1%&/0;S,=L_?CEXAV8 *8;N86$0TSL%@<?AR[=&*QG"#
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M     &%T;F8M,C R-# Y,#4N>'-D4$L! A0#%     @ IX,I6?4KO$8 "0
ME6@  !4              ( !_@,  &%T;F8M,C R-# Y,#5?9&5F+GAM;%!+
M 0(4 Q0    ( *>#*5FRP;(D\0L  !20   5              "  3$-  !A
M=&YF+3(P,C0P.3 U7VQA8BYX;6Q02P$"% ,4    " "G@RE9FH"H)4<(   O
M8P  %0              @ %5&0  871N9BTR,#(T,#DP-5]P<F4N>&UL4$L!
M A0#%     @ IX,I64U*5)JC&   FI0  !@              ( !SR$  &5A
M,#(Q,S@V."TX:U\Q.#!L:69E+FAT;5!+ 0(4 Q0    ( *>#*5F;+.<H-$<
M !=G 0 =              "  :@Z  !E83 R,3,X-C@P,65X,3 M,5\Q.#!L
M:69E+FAT;5!+ 0(4 Q0    ( *>#*5F\H@A"\TD  %*1 0 =
M  "  1>"  !E83 R,3,X-C@P,65X,3 M,E\Q.#!L:69E+FAT;5!+!08
..!P ' .0!  !%S      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ea0213868-8k_180life_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180lifesciences.com/20240905"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20240905.xsd" xlink:type="simple"/>
    <context id="AsOf2024-09-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="From2024-09-052024-09-05_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="From2024-09-052024-09-05_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-09-05" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-09-05" id="Fact000004">0001690080</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-09-05" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-09-05" id="Fact000010">2024-09-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-09-05" id="Fact000011">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-09-05" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-09-05" id="Fact000013">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-09-05" id="Fact000014">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-09-05" id="Fact000015">3000 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-09-05" id="Fact000016">&#160;Bldg. 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2024-09-05" id="Fact000017">&#160;Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-09-05" id="Fact000018">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-09-05" id="Fact000019">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-09-05" id="Fact000020">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-09-05" id="Fact000021">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-09-05" id="Fact000022">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-09-05" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-09-05" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-09-05" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-09-05" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2024-09-052024-09-05_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000027">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-09-052024-09-05_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-09-052024-09-05_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-09-052024-09-05_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000030">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-09-052024-09-05_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000031">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-09-052024-09-05_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-09-05" id="Fact000033">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
